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I 
Abbreviations 
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g  gram 
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IV 
Summary 
 
Multiple sclerosis (MS) is a common chronic inflammatory demyelinating disease of the 
central nervous system (CNS) affecting more than 1 million people worldwide. It mainly 
affects young adults and has a great impact on the social economic situation. Although 
several therapeutic drugs are available for slowing down progression or reducing number 
of relapses there is a clear need for more efficacious therapies. 
The peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor 
with anti-inflammatory effects, influences pro-inflammatory responses of several immune 
cell types during experimental autoimmune encephalomyelitis (EAE), the animal model of 
MS, which ameliorates the disease course and reduces neuronal damage. Hence, PPARγ 
seems to be a promising target for therapeutic treatment during EAE and MS. 
The aim of this thesis was to investigate the relevance of PPARγ specifically in myeloid 
cells for control of their inflammatory activity in vitro and in vivo. To this end, we made 
use of a conditional knock-out mouse model which exhibits targeted deletion of PPARγ in 
M-lysozyme (LysM)-expressing cells (LysM-PPARγKO mice) which comprise myeloid 
cells such as monocytes, macrophages, CNS-resident microglial cells as well as 
neutrophilic granulocytes. 
We observed significantly enhanced production of pro-inflammatory cytokines, 
chemokines and neurotoxic mediators by PPARγ-deficient (PPARγKO) primary microglial 
cells and macrophages compared to PPARγWT cells in vitro. Importantly, we could 
demonstrate in vivo, that LysM-PPARγKO mice exhibited an aggravated course of disease 
during the effector phase of EAE. This aggravation was accompanied by a more 
pronounced local inflammatory milieu within the CNS as pro-inflammatory cytokines such 
as tumor necrosis factor (TNF) α, interleucin (IL) -12 and IL-6 as well as chemokines like 
CCL2 and CCL5 were increasingly expressed in LysM-PPARγKO mice. Furthermore, this 
exacerbation was accompanied by an increase of CNS-invading macrophages and T cells 
as well as an increase in the activation status of PPARγKO myeloid cells, which show 
higher levels of Cluster of Differentiation  (CD40) and major histocompatibility complexes 
(MHC) -II expression. 
Furthermore, this thesis addressed the question which subgroup of myeloid cells is the 
main target for PPARγ-mediated regulation during EAE. By combining monocyte transfer 
and depletion experiments we identified the myeloid cell population that represents the 
main population regulated by PPARγ during EAE, i.e. Ly6Chi inflammatory monocytes. 
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Transfer of PPARγ-deficient monocytes into EAE-diseased mice resulted in a more 
pronounced aggravation of disease than the transfer of wildtype monocytes. In line with 
this, depletion of inflammatory monocytes during EAE not only ameliorated the disease 
course of both, LysM-PPARγKO and LysM-PPARγWT mice but also abrogated the 
differences observed during the effector phase in LysM-PPARγKO mice compared to their 
wildtype littermates. 
In summary, these data provide evidence that PPARγ controls the activation status of 
myeloid cells during autoimmune responses, thereby affecting the extent of CNS 
inflammation and hence neuronal damage in EAE. Therefore PPARγ in myeloid cells 
represents a promising therapeutic target for future treatment of CNS-infammation in MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
VI 
Zusammenfassung 
 
Multiple Sklerose ist eine weitverbreitete chronisch-entzündliche, demyelinisierende 
Erkrankung des Zentralen Nerven Systems (ZNS), an der weltweit mehr als 1 Millionen 
Menschen erkrankt sind. Sie betrifft überwiegend junge Erwachsene und hat daher eine 
große Bedeutung für die sozial-wirtschaftliche Lage. Obwohl verschiedene Medikamente 
verfügbar sind, die zum einen die Progredienz der Erkrankung verlangsamen oder die 
Anzahl der Schübe verringern, gibt es einen deutlichen Bedarf für wirksamere Therapien. 
Der Peroxisom Proliferator-aktivierte Rezeptor γ (PPARγ), ein nukleärer 
Transkriptionsfaktor mit anti-inflammatorischen Eigenschaften, beeinflusst die 
Entzündungsreaktionen verschiedener Immunzelltypen während der experimentellen 
autoimmunen Enzephalomyelitis (EAE), dem Tiermodell der MS. Dies führt zu einer 
Besserung des Krankheitsverlaufes und mindert neuronale Schäden. Daher scheint PPARγ 
einen vielversprechender Ansatz für eine therapeutische Behandlung der EAE und der MS 
zu sein. 
Ziel dieser Arbeit war es, die Relevanz von PPARγ speziell in myeloiden Zellen im 
Hinblick auf deren entzündliche Aktivierung in vitro und in vivo zu untersuchen. Um dies 
zu erreichen, wurde ein konditionales Knockout Maus-Modell genutzt, das eine Deletion 
der PPARγ-Expression ausschließlich in M-Lysozym (LysM) exprimierenden Zellen 
aufweist, darunter Monozyten, Makrophagen, ZNS-stämmige Mikroglia und neutrophile 
Granulozyten. 
Hierbei wurden in vitro in primären Mikrogliazellen und Makrophagen mit fehlerhaft-
expremiertem PPARγ (PPARγKO) signifikant erhöhte Produktionen von 
proinflammatorischen Zytokinen, Chemokinen und neurotoxischen Mediatoren im 
Vergleich zu Zellen mit funktionalem PPARγ beobachtet. In vivo zeigten Mäuse mit einem 
konditionalen PPARγ-Knockout in myeloiden Zellen (LysM-PPARγKO Mäuse) einen 
verschlimmerten Krankheitsverlauf während der Effektorphase der EAE. Diese 
Verschlechterung wurde begleitet von einem erhöhten inflammatorischen Milieu: die pro-
inflammatorischen Zytokine TNFα, IL-12 und IL-6, sowie die Chemokine CCL2 und 
CCL5 waren erhöht. Zudem wurde die Verschlechterung begleitet von einer erhöhten 
Anzahl in das ZNS einwandernder Makrophagen und T Zellen sowie eine Zunahme der 
Aktivierung der PPARγKO Zellen, die einen Anstieg der CD40- und MHC-II-Expression 
aufwiesen. 
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Des Weiteren befasste sich diese Arbeit mit der Fragestellung welche Untergruppe der 
myeloiden Zellen das Hauptziel für eine PPARγ-vermittelte Regulation während der EAE 
darstellt. Durch eine Kombination von Experimenten mit Monozyten-Transfer und 
-Depletion konnte eine bestimmte Population der myeloiden Zellen, die Ly6Chi 
inflammatorischen Monozyten, identifiziert werden, die die Hauptpopulation der 
myeloiden Zellen darstellt, die durch PPARγ während der EAE moduliert wird. Der 
Transfer von PPARγ-defizienten Monozyten in EAE-erkrankte Tiere ergab eine deutlich 
ausgeprägte Verschlechterung der Erkrankung im Vergleich zum Transfer von Wildtyp-
Monozyten. Dementsprechend führte die Depletion inflammatorischer Monozyten 
während der EAE nicht nur zu einer Verbesserung des Kranheitsverlaufs sowohl in LysM-
PPARγKO Mäusen als auch in LysM-PPARγWT Mäusen: Zuvor beobachtete Unterschiede 
während der Effektorphase zwischen LysM-PPARγKO Mäuse und Wildtyp Kontrolltieren 
waren aufgehoben. 
Zusammenfassend belegen diese Daten, dass PPARγ den Aktivierungsstatus von 
myeloiden Zellen während der ZNS Autoimmunität kontrolliert. Zudem begrenzt PPARγ 
in myleoiden Zellen das Ausmaß der ZNS-Entzündung und die nachfolgenden neuronalen 
Schäden während der EAE. Daher stellt PPARγ in myeloiden Zellen ein 
vielversprechendes therapeuthisches Ziel für eine zukünftige Behandlung von ZNS-
Entzündungen in der MS dar. 
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1 Introduction 
 
1.1  The immune system 
 
Organisms are ubiquitously exposed to pathogens like bacteria, viruses, fungi, or parasites. 
These organisms can enter the body through the skin, the respiratory tract, or mucosal 
epithelium1. 
The immune system is a biological defense mechanism, which protects the organism from 
those pathogens by identifying and eliminating them. In vertebrates, the immune response 
is classified into two components: 
1) The innate immune response, which is very fast and mediates the first defense in a 
generic way within the first hours after infection and  
2) Whereas the innate immune response is based on conserved receptors, recognizing 
distinct structures of pathogens and present in all multicellular organisms, only 
vertebrates possess a more antigen-specific immune response: the adaptive immune 
system, which specifically recognizes proteins on pathogens1. The adaptive 
immune response occurs later than the innate system. It triggers elimination of 
pathogens or infected cells in a more specific and a more effective way. 
Importantly, the adaptive immune response mediates immunological memory, 
which allows a more rapid immune response at the time of a second infection with 
the same pathogen1. 
 
1.1.1 The innate immune system 
 
If microorganisms try to enter the organism through the skin, the respiratory tract, or the 
mucous membranes, the innate immune response is the first barrier of defense.  
Several cells and mechanism, such as natural killer cells, mast cells, eosinophils, and 
basophils, phagocytic cells like dendritic cells (DCs), macrophages, and neutrophils and 
the humoral component (e. g. the complement system and serum proteins) compose the 
innate immune response.  
However, only monocytes / macrophages and microglial cells are important cells of the 
innate immune system in this thesis. Monocytes are the premature macrophages, 
circulating in the blood stream. Microglia are the resident macrophages of the central 
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nervous system (CNS)2. However, monocytes, macrophages, and microglia are thought to 
be of myeloid origin and derive from monocytic lineage3. Importantly, they recognize 
molecules specifically associated with pathogens, namely, pathogen-associated molecular 
patterns (PAMPs) by pattern recognition receptors (PRRs)1,4. They can phagocytose these 
antigens and activate further macrophages by secretion of cytokines like interleukin (IL)-
1β, IL-6 and tumor necrosis factor (TNF) α or granulocyte macrophage colony-stimulating 
factor (GM-CSF). Furthermore, macrophages can release chemokines, attracting immune 
cells to the side of inflammation. In addition, CCL2, secreted by different tissue cells, e. g. 
hepatic myofibroblasts5 or astrocytes in the CNS6, attracts monocytes, macrophages and 
microglia. 
 
The importance of the innate immune system is to keep the infection in check for the first 4 
to 7 days, until the adaptive immune response begins1. 
During the first days of infection, the major functions of the innate immune system are: 
- Identification of pathogens, 
- Recruitment of further immune cells to the site of infection by secretion of proteins 
of the complement system and chemokines 7, 
- Activation of the adaptive immune system by cytokines. 
 
1.1.2 The adaptive immune system 
 
Beside tasks, regarding the innate immune system like antigen recognition and immune 
cell recruitment, macrophages and microglia also belong to the adaptive immune response 
as they can activate T cells, which are together with B cells the most important cells of the 
adaptive immune response. Both, T cells and B cells derive from a common lymphatic 
progenitor cell in the bone marrow. While B cells also mature in the bone marrow, 
differentiation into a T cell proceeds in the thymus1. However, in this thesis, T cells, 
macrophages and microglial cells play a major role, therefore this part focuses on these 
cells. 
T cells possess a specific T cell receptor (TCR). The specificity of the receptor is not 
encoded in the genome, but each receptor is distinct due to somatic recombination. 
Therefore, every T cell carries a unique receptor with a distinct antigen-specificity, which 
results in a massive repertoire of antigen-recognition by the adaptive immune system1. 
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As T cells are not able to recognize “free” antigens, antigen recognition by the TCR 
requires presentation of antigen-derived peptides bound to molecules of the major 
histocompatibility complexes (MHC), also known as human leukocyte antigen (HLA) in 
humans. T cells, classified by expressing cluster of differentiation (CD) 8 on their surface, 
CD8+ T cells, recognize endogenous peptides, which are presented on MHC class I   
(MHC-I) molecules on a cell-surface1. 
More prominent for the content of this thesis are CD4+ T cells, which recognize peptides 
presented on MHC-II molecules: Antigen presenting cells (APCs), e. g. DCs, 
macrophages, or microglia take up exogenous pathogens by phagocytosis or endocytosis 
and present peptides in the context of MHC-II on their surface. Beside the recognition of 
antigens by the MHC–TCR-complex, termed signal 1, full activation of naïve T cells 
necessitates further signals like CD80 and CD86 (signal 2). An important costimulatory 
molecule required for the activation of macrophages and microglial cells is CD40, which is 
recognized by CD40L on the T cell surface.  
As a third signal T cell activation requires pro-inflammatory cytokines (signal 3)8. 
Upon activation and expansion, CD4+ T cells, also termed as T helper (TH) cells, 
differentiate into different T cell subsets, which are characterized by different cytokine 
profiles and distinct effector functions1,9. Thereby, different cytokine profiles trigger 
certain T cell subpopulations: For example, presence of interferon (IFN) γ and IL-12 
trigger differentiation into TH1 cells. The main purpose of TH1 cells is to activate 
macrophages10. During the last decade, a new subset of TH-cells was described11-13: The 
TH17 cells, which are induced by transforming growth factor (TGF) β together with IL-6. 
Beside their importance in clearance of extracellular pathogens like Klebsiella pneumonia 
or Candida albicans14,15, TH17 cells play an important role in the development and 
perpetuation of different autoimmune diseases like multiple sclerosis (MS) or 
colitis9,11,16,17. 
 
1.2 Self-tolerance and Autoimmunity 
 
The adaptive immune response is a system to specifically defend infection. As mentioned 
before, based on somatic recombination, various T cells carry their specific TCR on the 
surface. There is no doubt that T cells recognizing self-antigens develop. Different 
mechanisms, termed central and peripheral tolerance, overcome the development of 
autoimmunity: central tolerance take place during the development of T cells in the 
Introduction 
   4 
thymus. The selection of T cells is controlled by the binding strength of the TCR and the 
MHC-peptide-complex: If an immature T cell receives a too weak signal, the T cell 
undergoes apoptosis (positive selection). Within the thymus, self-antigens, derived from 
the thymus epithelium or the bloodstream, are presented by macrophages and DCs in 
association with MHC to maturing T cells. If a T cell recognizes a self-antigen by its TCR, 
apoptosis is induced (negative selection)18. 
Although many auto-reactive T cells and B cells are eliminated by central tolerance, some 
auto-reactive lymphocytes are present in the periphery. Peripheral tolerance suppresses 
activation of these T cells by different mechanisms: Self-antigens that are presented in 
immune privileged areas like the CNS or the eye in a low concentration do not induce 
activation of auto-reactive T cells (ignorance)19. As mentioned before, beside antigen-
recognition (signal 1), activation of T cells requires also signal 2 (costimulatory molecules) 
and 3 (cytokines). If a T cells obtains only signal 1 and signal 2 and 3 is missing, the cell 
becomes tolerant towards this antigen (anergy)20.  
Breakdown of immunological tolerance results in the development of autoimmunity. 
Autoimmune disorders can be systemic like rheumatoid arthritis or systemic lupus 
erythematosus or organ-specific like type I diabetes or MS. 
Despite a wide range of analysis, little is known about the development of autoimmune 
disorders. However, some mechanisms are thought to play a role in progression of 
autoimmunity: Two major factors for development of autoimmunity are environmental 
factors and the genetics. Different twin studies revealed a strong involvement of certain 
genes in the development of autoimmune diseases like type I diabetes21. The most 
prominent protein for genetic disposition to autoimmune disease is the MHC-protein. 
Several autoimmune diseases have been associated with certain genetic alleles of the 
human HLA1.  
Furthermore, analysis of different patient populations revealed an important role for 
environmental factors for the development of autoimmune disorders 23 24.  
There are different hypothesis for the development of autoimmune diseases, like infection 
of APCs that modifies their behavior as antigen-presenting cells, binding of a foreign 
antigen to self-antigen, resulting in immune reactivity against the self-antigens, or a cross 
reaction of self-antigens with endogenous antigens (molecular mimicry)1, like dengue 
fever inducing lupus25 or Epstein barr virus, which is associated with MS26. 
Immune responses against self-antigens result in inflammation, and, as a consequence, in 
severe tissue damage of the particular organ. 
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1.2.1 Autoimmunity within the central nervous system 
 
The CNS has long been considered to be a non-immunological system27. However, studies 
of systemic inflammation and tissue damage changed this view28. MS is one of the most 
common chronic and inflammatory disorders of the CNS.  
 
1.2.1.1 Multiple Sclerosis 
 
MS is a common neurological autoimmune disease, that typically starts during early 
adulthood with a high prevalence in Caucasians29,30. Its pathology is characterized by 
inflammation, demyelination, and axonal damage within the CNS31,32. Approximately 85% 
of MS patients start with a relapsing-remitting course, which is characterized by 
unpredictable recurring relapses, intermediated by a remission, with no signs of disease 
activity. While the number of clinical relapses decreases over the time, most patients 
develop progressive neurological deficits that are independent of relapses. In contrast to 
the relapsing-remitting course, approximately 15% of MS patients do not have acute 
relapses, but a slowly progressive disease (primary progressive MS)27,33. 
Although the etiology of MS is still unclear, many studies indicate that environmental 
factors play a role in MS development34,35. For example, MS relapses are often associated 
with viral infections26, or migration from high- to low-risk areas before adolescence 
reduces the risk of MS development34. One critical factor associated with risk of MS 
development is a certain gene for the HLA class II, which is associated with MS and plays 
a role in clinical manifestation as well as influences the disease course of MS36.  
Neuropathologically, MS is characterized by sclerotic lesions within the CNS, which are 
characterized by demyelination, leading to neurological dysfunction. The current concept 
about the cascade of pathophysiologic events leading to MS pathology consists of an initial 
activation of myelin-specific CD4+ T cells in the periphery by professional APCs 
presenting self-antigens or antigens, which are cross-reactive to self-antigens37,38. 
Especially the TH1 and TH17 subsets of CD4+ T cells have been implicated in disease 
mediation 31,39-41.  
These activated T cells proliferate and migrate into the CNS across the blood brain barrier 
(BBB). It has recently been shown that especially during disease initiation, this migration 
step requires the chemokine receptor CCR6 and its ligand CCL20, which is highly 
expressed in epithelial cells of the choroid plexus42.  
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Within the CNS, T cells recognize myelin peptides in association to the MHC-II-complex 
on the surface of local APCs, which consist of perivascular macrophages and microglial 
cells43. This local reactivation of auto-reactive T cells and their interaction with local 
immune cells results in an inflammatory response within the CNS with release of pro-
inflammatory cytokines and chemoattractant proteins29,44-47. This causes an attraction of 
further immune cells, such as T and B cells and macrophages, which infiltrate the site of 
inflammation and contribute to maintenance of inflammation by further release of pro-
inflammatory mediators and neurotoxic mediators, ultimately resulting in destruction of 
the myelin sheath.  
Current treatment options for MS therapy consist of IFNβ, glatiramer acetate, and 
natalizumab. IFNβ reduces relapse-frequency and severity in relapsing remitting MS48. Its 
immunomodulatory activities are broad and encompass reduction of T cell activation and 
proliferation as well as a reduction in BBB permeability. Glatiramer acetate is a synthetic 
mixture of amino acids resembling the composition of myelin basic protein (MBP), a 
major self antigen of the CNS49. Treatment of MS patients results in shift from TH1 cells to 
TH2 cells thereby suppressing T cell-mediated inflammatory responses50. Another 
promising therapeutic agent is natalizumab, a monoclonal antibody against very late 
antigen-4, expressed on activated T cells. Blocking of very late antigen-4 very efficiently 
inhibits T cell migration through the BBB and hence invasion of auto-reactive T cells into 
the target organ51. 
 
1.2.1.2 Experimental autoimmune encephalomyelitis 
 
In order to investigate the mechanism responsible for development of MS, Rivers et al. 
established a model for MS in 193352: the EAE, which is commonly used for experimental 
MS research. 
EAE is an inflammatory disease of the CNS, which is induced by injection of proteins 
derived from myelin, like myelin oligodendrocyte protein (MOG), MBP, or proteolipid 
protein (PLP), into susceptible animals, such as mice, together with Freund’s adjuvant as 
an immunopotentiator. In addition, pertussis toxin is injected, which leads to 
permeabilization of the BBB. 
The disease is characterized by perivascular infiltrates, leading to neurological symptoms 
like paralysis or ataxia, beginning approximately one week after immunization. The cells, 
which predominantly initiate the disease, are CD4+ T cells, as transfer of MOG-reactive 
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CD4+ T cells isolated from EAE-diseased animals results in appearance of disease in 
healthy recipient mice53.  
It is known, that T cells of TH1 phenotype mediate CNS inflammation during EAE54. 
However, during the last years several studies identified TH17 cells to be involved in the 
induction of CNS-autoimmunity like EAE and MS39,55,56. The chemokine CCL20, 
expressed by epithelial cells of the choroid plexus, and its receptor CCR6, which is 
predominantly found on TH17 cells, are involved in T cell migration into the CNS42,57. It 
was shown that T cells migrate through the BBB into the CNS in two steps: A first wave of 
TH17 cells migrate into the un-inflamed CNS in a CCR6-dependent manner. In a second 
wave, TH17 and TH1 cells migrate in a CCR6-independent way42.  
Within the CNS, these invading T cells secrete inflammatory mediators, like IFNγ and 
GM-CSF, which activates microglia and macrophages47,58 and lead to secretion of further 
cytokines and chemokines in the inflammed tissue6,59. This results in an inflammatory 
milieu within the CNS, recruiting and activating further immune cells like T cells, 
macrophages, and microglia into the CNS60,61. Furthermore, macrophages and microglia 
release neurotoxic mediators, like TNFα and nitric oxide (NO), leading to destruction of 
myelin sheath and astrocytes45,62-64.  
EAE is generally divided into an initial priming phase, that is mediated by auto-reactive 
T cells followed by the effector phase, where macrophages and microglia get activated by 
invading T cells, inducing expression of neurotoxic mediators, which leads to 
demyelination and neurodegeneration45,62,63. 
 
1.2.1.3 The role of microglia and macrophages for the development of MS and EAE  
 
Microglial cells are resident macrophages of the CNS, scanning the tissue persistently and 
showing changes in morphology upon activation2. They exhibit macrophage-like functions, 
i.e. phagocytosis, antigen presentation, production of reactive oxygen species (ROS), NO, 
and pro-inflammatory cytokines64,65. 
MS and EAE have been considered to be mediated by T cells as they crucially amplify 
CNS autoimmunity29,66. As mentioned before, T cells have been proven to initiate the 
disease. However, effector mechanisms leading to inflammation, demyelination and 
neuronal damage are thought to be mainly provided by other cells like infiltrating 
macrophages and microglia67. In the last years, these cells have been identified as main 
effectors of disease progression47,68 as they both play a crucial role for T cell reactivation 
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within the CNS69,70 and directly contribute to demyelination and axonal damage by 
secretion of pro-inflammatory mediators such as ROS, NO and TNFα63,64. 
 
1.3 Peroxisome proliferator-activated receptor γ  
 
The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear transcription 
receptor that belongs to the superfamily of nuclear hormone receptors. It is ligand-
activated and, upon ligand binding, PPARγ forms a heterodimer with the retinoic X 
receptor. This complex activates transcription by binding to a specific deoxyribonucleic 
acid (DNA) element, termed the PPAR response element, in the promoter region of target 
genes, thus influencing gene transcription71-73. In addition, anti-inflammatory effects of 
PPARγ are mediated by interfering with pro-inflammatory transcription factors, such as the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) or the nuclear 
factor of activated T cells (NFAT)74,75, which results in modulation of immune responses, 
cellular proliferation, and differentiation. So far, anti-inflammatory effects of PPARγ on 
immune responses have been demonstrated for dendritic cells76-78, lymphocytes 77,79, 
neuronal cells and astrocytes80, monocytes / macrophages72,75,81,82, and microglia83.  
Naturally occurring endogenous agonists for PPARγ are polyunsaturated fatty acids, 
arachidonic acid metabolites (15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2))84,      
15-hydroxyeicosatetraenoic acid (15-HETE)85, or fatty acid-derived components like        
9- and 13- hydroxy octadecadienoic acid (HODE)86. Beside these endogenous ligands, 
synthetic ligands like Pioglitazone (Pio) and Rosiglitazone were approved drugs for the 
therapy of diabetes type II in Germany since 2007 and 1999, respectively. Due to several 
adverse reactions like an increased risk for bladder cancer, cardiovascular diseases and 
liver diseases87, competent authorities suggest to give these medication only with high 
caution since 2011. However, the anti-inflammatory effect of PPARγ-activation has been 
proven and can be used for treatment of several inflammatory diseases. 
 
1.3.1 PPARγ  and multiple sclerosis 
 
Several EAE-studies suggest that PPARγ is a promising immunomodulatory and 
therapeutic target for treatment of MS, as systemic activation of PPARγ by application of 
synthetic or endogenous ligands has been shown to reduce the incidence and severity of 
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disease, local CNS-inflammation, as well as demyelination and axonal damage during 
EAE pathology55,88-90. 
Our group has previously shown that activation of PPARγ in DCs decreases CD4+ T cell 
response in vitro. Furthermore, knockout of PPARγ in DCs resulted in an enhanced 
CD4+ T cell response. In in vivo experiments it was shown, that PPARγ-activated DCs, 
transferred into mice, induce prolonged T cell anergy upon antigen-specific interaction 
with CD4+ T cells 77. 
Furthermore, PPARγ in CD4+ T cells also plays a central role for the development of EAE, 
as activation of PPARγ selectively interferes with TH17 differentiation55 and results in 
reduced auto-reactive TH17 responses in the EAE model89. 
Interestingly, Klotz et al. showed reduced levels of PPARγ in peripheral blood 
mononuclear cells (PBMCs) of MS patients, compared to healthy controls91. Moreover, 
activation of PPARγ in PBMCs derived from MS patients reduced inflammatory responses 
upon stimulation 91,92, identifying PPARγ in MS patients as promising target for regulation 
of inflammation. 
Therefore, PPARγ seems to be an auspicious target for the reduction of immune responses 
during MS.  
 
1.4 Importance of the CCL2 / CCR2-axis to reinforce EAE 
pathology 
 
CCL2 and its receptor CCR2 have been shown to play an important role during CNS 
autoimmunity, as CCR2-deficient mice are resistant to EAE93-95 and administration of 
CCL2-antibodies ameliorates established EAE pathology96. Geissmann et al. identified two 
different monocyte populations in both, humans and mice. In mice they can be 
distinguished based on their CCR2 expression97: The “inflammatory monocytes” are 
CCR2+Ly-6ChiCX3CR1lo, and the “resident monocytes” are CCR2-Ly-6CloCX3CR1hi.  
Inflammatory monocytes play a crucial role for the inflammation within the CNS98-100 and 
especially during EAE99,100. EAE experiments with CCR2 knockout mice as well as 
specific cell depletion of CCR2+ peripheral monocytes during EAE showed a reduction of 
the severity of disease100. Upon CNS-inflammation astrocytes have been proven to secrete 
CCL2, which can attract inflammatory monocytes into the CNS6. 
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Interestingly, macrophages can switch from a regulatory phenotype to an inflammatory 
phenotype and back, upon specific signals101 and several data sets indicate that PPARγ 
activation skews monocytes towards a regulatory phenotype in mice and in humans102-104.  
However, the role of PPARγ in myeloid cells on the inflammation is not yet fully 
understood and needs to be elucidated. Therefore, this thesis focuses on the role of PPARγ 
in myeloid cells on the inflammation during EAE. 
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2 Aim of the thesis 
 
MS is the most common neuroinflammatory disease in North America and Europe. 
Because of its expeditious etiopathology and the severity of disease, it is important to 
further investigate the disease and develop new therapeutic approaches to alleviate the 
gravity of disease. A common model for MS research is the animal model EAE. 
Several EAE-studies focused on encephalitogenic T cells, which play a crucial role in the 
pathogenesis of EAE. However, recently different studies identified a prominent role for 
myeloid cells such as monocytes, macrophages, and microglia for the progression of EAE. 
Since PPARγ has been demonstrated to modulate pro-inflammatory responses by different 
myeloid cell populations in vitro, this work deals with the question whether PPARγ plays a 
role in myeloid cells during disease initiation and progression of EAE. 
 
In particular, the following questions were addressed: 
 
1) Does lack of PPARγ in myeloid cells influence the disease course during EAE?  
 
2) Does cell-type specific knock-out of PPARγ alter immune responses of 
macrophages and microglia in vitro and in vivo? 
 
3) What is the role of PPARγ in CCR2+Ly-6ChiCX3CR1lo inflammatory monocytes 
during the pathogenesis of EAE? 
 
4) Which myeloid cells are the main targets for PPARγ activation in vivo? 
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3 Materials and Methods 
 
3.1 Materials 
 
3.1.1 Equipment 
 
Autoclave       Belimed, Köln 
Balances       Sartorius, Göttingen 
Beakers (50 ml, 100 ml, 150 ml, 250 ml, 500 ml)  Schott, Mainz 
Cell Separator, Auto MACS  Miltenyi Biotec, Bergisch 
Gladbach 
Centrifuges (Multifuge3 S-R, Biofuge fresco,   Heraeus, Hanau 
Biofuge pico) 
Counting Chamber, Neubauer improved   Brand, Wertheim 
Disperser, Ultraturrax     IKA Werke, Staufen 
ELISA-Reader, SpectraMAX 250    Molecular devices, Ismaning 
Flow cytometer, FACS CantoII    BD Biosciences, Heidelberg 
Heating block, TheromStat plus    Eppendorf, Hamburg 
Incubators, HERAcell     Heraeus, Hanau 
Injectionpump WPI SP 2101WZ    WPI, Aston, UK 
Magnet stirrer, IKAMAG     IKA Werke, Staufen 
Measuring cylinders (50 ml, 100 ml, 250 ml  Schott, Mainz 
500ml) 
pH-meter       WTW, Weilheim 
Pipettes Pipetboy     IBS, Fernwald 
 Pipetman     Gilson, Heidelberg 
  Reference     Eppendorf, Hamburg 
Preparation Instruments     Labotec, Göttingen 
Sieves, steel       University Bonn, Department
        ″Feinmechanik″ 
Sonicator, Sonopuls      Bandelin Electronic, Berlin 
Spectrophotometer, Nanodrop ND 1000 Thermo Scientific, Wilmington, 
USA 
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Thermocycler Biometra, Göttingen 
Thermocycler, real-time PCR, ABI Prism 7900HT Applied Biosystems, Darmstadt 
Threaded bottles (100 ml, 250 ml, 500 ml, 1 l, 2 l) Schott, Mainz 
Ultrapure Water System, NANOpure Diamont Barnstead Thermolyne, 
Dubuque, USA 
Vortexer VWR International, Darmstadt 
Waterbath, TW8 Julabo, Seelbach 
Workbench, sterile, HERAsafe Heraeus, Hanau 
 
3.1.2 Software 
 
EndNote X3       Thomson ISI Research Soft, USA 
FACS Diva V6.1.1      BD Biosciences, Heidelberg 
FlowJo V8.8.6      Treestar, Inc., USA 
Illustrator 10.0.3      Adobe, USA 
Microsoft Office 2008     Microsoft, USA 
ND-1000 V3.5.1  NanoDrop Technologies, 
Wilmigton, USA 
Prism 4 for Macintosh     GraphPad Software, USA 
SDS 2.2       Applied Biosytems, Darmstadt 
SOFTmax pro 2.6.      Molecular devices, Ismaning 
 
3.1.3 Consumables 
 
Cryo vials       VWR International, Darmstadt 
FACS tubes, polystyrene, 12 x 75mm   Sarstedt, Nümbrecht 
Filter, sterile (0.2 µm, 0.45 µm)    Whatman, Dassel 
Injection needles (27G, 26G, 20G)    Braun, Melsungen and 
        BD Bioscience, Heidelberg 
Gloves, DermaClean      Ansell, Red Bank, New Jersey, USA 
Microtiter plates, 96-well round and flat bottom  Greiner bio-one, Solingen 
Microtiter plates, 96-well, transparent   Greiner bio-one, Solingen 
Microtiter plates, 384-well, MicroAmp   Applied Biosystems, Darmstadt 
Optical adhesive film, MicroAmp    Applied Biosystems, Darmstadt 
Materials and Methods 
   14 
Parafilm       Pechiney Plastic Packaging, Chicago 
Pasteur pipettes (150 mm, 230 mm)    Roth, Karlsuhe 
Pertussis toxin, from Bordetella pertussis   Sigma-Aldrich, München 
Petri dishes, 100 mm, 150 mm    Greiner bio-one, Solingen 
Pipette tips, (10 µl, 20 µl, 200 µl, 1000 µl)   Greiner bio-one, Solingen 
Pipette tips, nuclease free (10µl, 20 µl, 200 µl, 1000 µl) Nerbeplus, Winsen / Luhe 
Pipettes, glass, (5 ml, 10 ml, 25 ml)    Brand, Wertheim 
Pipettes, plastic, (5 ml, 10 ml, 25 ml)   Sarstedt, Nümbrecht 
Polyamide tissue, Gaze     Labomedic, Bonn 
Polypropylene tubes (15 ml, 50 ml)    Greiner bio-one, Solingen and 
        Sarstedt, Nümbrecht 
Reaction tubes (0.2 ml)     Nerbeplus, Winsen / Luhe 
Reaction tubes (0.5 ml, 1 ml, 1.5 ml, 2 ml)   Sarstedt, Nümbrecht 
Scalpel       Feather, Osaka, Japan 
Syringes (1 ml, 2 ml, 5 ml, 10 ml, 20 ml)   BD Bioscience, Heidelberg 
Tissue Culture Plates (6-, 12-, 24-, 48-, 96-well)  TPP, St. Louis USA and 
        Sarstedt, Nümbrecht 
Tissue culture plates, 100 x 20 mm    Sarstedt, Nümbrecht 
Tissue culture flasks, 75 cm2     Sarstedt, Nümbrecht 
 
3.1.4 Chemicals, reagents and Kits 
 
Bovine serum albumin (BSA)    Roth, Karlsruhe 
1-Bromo-3-Chloropropane (BCP)    Sigma-Aldrich, München 
Complete Freund’s adjuvant (CFA)    Difco, Detroit, USA 
Counting beads, CountBright Absolute Counting Beads Invitrogen, Frankfurt 
Collagenase       Roche, Basel, Switzerland 
Dimethylsuloxide (DMSO)     Merck, Darmstadt 
Ethanol, absolut      Merck, Darmstadt 
Ethanol, absolut for nucelase     Aplichem, Darmstadt 
Ethylenediaminetetraacetic acid (EDTA)   Sigma-Aldrich, München 
Fetal calf serum (FCS)     PAA, Cölbe 
Fixation / Permeabilization Kit, BD Cytofix / Cytoperm BD Bioscience, Heidelberg 
Gey’s balanced salt solution (GBSS)   Sigma-Aldrich, München 
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Heparin       Ratiopharm, Ulm 
Inhibitors, Monensin and Brefeldin A   eBioscience, Frankfurt 
Isopropyl alcohol      Aplichem, Darmstadt 
L-Glutamine       Lonza, Köln 
Lipopolysaccharide (LPS) from     Sigma-Aldrich, München 
Echerichia coli O127:B8   
Medium, DMEM      Invitrogen, Darmstadt 
Medium, RPMI 1640      Invitrogen, Darmstadt 
Mycobakterium tuberculosis H37 RA, dessicated  Difco, Detroit, USA 
non-essential amino acids     PAA, Pasching, Austria 
Nuclease-free water      Applied Biosystems, Darmstadt 
Paraformaldehyde (PFA)     Fluca, Buchs 
Penicillin / Streptomycin     PAA, Pasching, Austria 
Pioglitazone (for cell culture)    Alexis Biochemicals, Lörrach 
Percoll        GE Healthcare, Freiburg 
Phenol-Chloroforme      Roth, Karlsruhe 
Phorbol myristate acetate (PMA)    Sigma-Aldrich, München 
Phosphat buffered saline (PBS)    Biochrom, Berlin 
Phosphat buffered saline (PBS), solution   Sigma-Aldrich, München 
Poly-L-lysine hydrobromide     Sigma-Aldrich, München 
RNAlater        Qiagen, Hilden 
RNeasy-Kit       Qiagen, Hilden 
Sodium azide (NaN3)      Sigma-Aldrich, München 
Sodium bicarbonat (NaHCO3)    Sigma-Aldrich, München 
SuperScript III      Invitrogen, Frankfurt 
TaqMan Gene Expression Master Mix   Applied Biosystems, Darmstadt 
TaqMan Power SYBR Green Master Mix   Applied Biosystems, Darmstadt 
Tibromoethanol (Avertin)     Sigma-Aldrich, München 
Trypane blue (0.4%)      Lonza, Köln 
Trysin EDTA       Invitrogen, Frankfurt 
TriReagent       Invitrogen, Frankfurt 
Triton X-100       Sigma-Aldrich, München 
Tween20       AppliChem, Darmstadt 
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3.1.5 Primer and Probes 
 
For quantitative real-time RT-PCR the following primers were used: 
 
Target  Orientation    Sequence     
IFNγ   forward  5´-GAACTGGCAAAAGGATGGTGA-3´ 
   reverse  5´-TGTGGGTTGTTGACCTCAAAC-3´ 
IL-1β   forward  5´-GCCCATCCTCTGTGACTCAT-3´ 
   reverse  5´-AGGCCACAGGTATTTTGTCG-3´ 
IL-6   forward  5´-AAGTCGGAGGCTTAATTACACATGT-3´ 
   reverse  5´-CCATTGCACAACTCTTTTCTCATT-3´ 
TNFα   forward  5´-CATCTTCTCAAAATTCGAGTGACAA-3´ 
   reverse  5´-TGGGAGTAGACAAGGTACAACCC-3´ 
 
Quanti Tect Primer assays for analysis of iNOS and IL-12 were purchased from Qiagen. 
Examination of the chemokines CCL2, CCL3, CCL5, and CXCL10 as well as internal control of 
GAPDH were made with FAM-labeled TaqMan Probes. 
 
To analyze PPARγ-deletion in cells, following primers were used: 
 
Target  Orientation    Sequence     
PPARγ   forward  5´-TATCACTGGAGATCTCCGCCAACAGC-3´ 
reverse   5´-GTCACGTTCTGACAGGACTGTGTGAC-3´ 
 
3.1.6 Buffers and solutions 
 
ACK-Lysis Buffer 
ACK-Lysis Buffer for lysing of red blood cells, 16.58 g NH4CL, 2 g KHCO3, and 74.4 mg 
Na2EDTA were dissolved in 2000 ml H2O and adjusted to pH 7.2-7.4. ACK-Lysis Buffer 
was stored at room temperature. 
 
Fetal calf serum (FCS) 
FCS was heat-inactivated at 56°C for 30 min and stored at –20°C at 50 ml aliquot. 
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0.5 mM EDTA 
For a solution of 0.5 mM, 186.1 g EDTA and 20 g NaOH were dissolved in 1000 ml ultra-
pure water and pH was adjusted to 7.8 - 8.0. EDTA was stored at room temperature after 
autoclavation. 
 
Fluorescence-activated cell sorting (FACS)-buffer 
For flow cytometric analysis, cells were stained, washed, and stored in FACS-buffer, 
which is 1 x PBS with 1% (v/v) FCS and 0.1% (v/v) NaN3. FACS-buffer was stored at 
+4°C. 
 
Brain perfusion buffer 
Before isolation of brain and spinal cord, mice were perfused with GBSS with 2% heparin. 
 
4% (w/v) PFA solution 
8 g PFA was dissolved in 200 ml 1 x OBS by gradual heating. The pH was adjusted to 7.4 
and aliquots were stored at –20°C. 
 
Phosphat buffered saline (PBS) 
1 x PBS was adjusted to pH 7.4, aliquoted à 500 ml, autoclaved, and stored at +4°C. 
 
Buffers for Enzyme-linked Immunosorbent assay (ELISA) 
 
Coating buffer (1 M NaHCO3) 
0.84 g NaHCO3 were dissolved in 100 ml A. bidest. The pH was adjusted to 8.2. 
 
Blocking buffer (1 % BSA) 
0.1 g BSA was dissolved in 100 ml PBS by agitation. 
 
Washing buffer (0.05 % Tween) 
100 µl Tween20 were added to 2 l PBS. 
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3.1.7 Media 
 
Medium for bone marrow macrophages (BM-M) 
DMEM (high glucose) 
10%  (v/v) FCS 
105 U Penicillin / 0.1mg/ml Streptomycin 
50µM β-Mercaptoethanol (β-ME) 
2mM L-Glutamin 
30% (v/v) supernatants from M-CSF transduced L929 cell-line 
 
Medium for primary microglia (pMg) 
DMEM (high glucose) 
10%  (v/v) FCS 
1%  (v/v) non-essential amino acids 
105 U Penicillin / 0.1mg/ml Streptomycin 
50µM β-ME 
2mM L-Glutamin 
 
Media for T cells 
RPMI 1640 
10% (v/v) FCS 
105 U Penicillin / 0.1mg/ml Streptomycin 
50µM β-ME 
2mM L-Glutamin 
3.1.8 Peptides and Proteins 
 
MOG35-55        Biotrend, Köln 
MOG35-55        Pineda, Berlin 
recombinant mouse IL-12  R&D Systems, Minneapolis, 
USA 
recombinant mouse IFN γ  R&D Systems, Minneapolis, 
USA 
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3.1.9 Antibodies 
 
Fluorochrome conjugated antibodies for flow cytometry 
The following antibodys were used for flow cytometric analysis of extracellular surface 
molecules or for intracellular cyokine staining. Antibodies, labeled with Phycoerythrin 
(PE), Pacific blue, Allophycocyanin (APC), Fluoresceinisothiocyanat (FITC), Biotin, or 
tandem conjugate Peridinin Chlorophyll Protein with a cyanin dye (PerCP-Cy5.5), were 
used at previously determined concentrations. 
 
Antigen Isotype  Clone  Conjugate  Company  
CD4  Rat IgG2b, κ  GK 1.5 PE   eBioscience  
                           Pacific blue  eBioscience  
CD8a  Rat IgG2a, κ  53-6.7  PE   BD Bioscience 
CD11b Rat IgG2b, κ   M1/70  APC   eBioscience  
CD115 Rat IgG2a, κ   AFS 98 Biotin   eBioscience  
CD40  Rat IgG2a, κ  1C10  PE   eBioscience  
CD45  Rat IgG2b, κ   30-F11 Pacific blue  eBioscience 
       FITC   eBioscience  
IFNγ  Rat IgG1, κ  MG1.2  PE   eBioscience  
IL-17A Rat IgG2a, κ   eBio17B7 APC   eBioscience 
       PE   eBioscience  
Ly-6C  Rat IgG2c   HK1.4  PerCP-Cy5.5  eBioscience  
Ly-6G  Rat IgG2a, κ   1A8  APC   BD Bioscience 
       FITC   BD Bioscience 
MHC-II Mouse IgG2a, κ AF6-120.1 PE   BD Bioscience 
TNFα  Rat IgG1, κ   MP6-XT22 PE   eBioscience  
 
Blocking Fc fragments to avoid unspecific signals, Fc Receptor blocker 2.4G2 was used. 
 
Antibodies for ELISA 
Primary and secondary antibodies for TNFα ELISA as well as the ELISA-Kit CCL2-
ELISA Ready-SET-Go were purchased from eBioscience.  
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Antibodies for immunohistochemistry 
 
Immunohistochemical analysis were kindly performed by the laboratory of Prof. M. Prinz, 
Freiburg. Following antibodies were used: 
 
Antigen    Clone   Company    
amyloid precursor protein (APP)  polyclonal goat  Chemicon, Temecula, USA  
CD3      CD3-12  BD Pharmingen, Germany 
MAC-3     M3/84   BD Biosciences, Heidelberg  
 
3.1.10 Antibody-coated beads for Magnetic Cell Separation 
 
For magnetic-activated cell sorting (MACS) following antibody-coated beads from 
Miltenyi Biotec, Bergisch Gladbach were used: 
anti-CD4, anti-CD-8, anti-CD11b, anti-CD11c, anti-CD19, and anti-Biotin. 
 
3.1.11 Mouse strains 
 
All mice were bred and maintained under specific pathogen-free conditions at the “Haus 
für Experimentelle Therapie” or at the “Instituts of Molecular Medicine and Experimetal 
Immunology” at the University Hospital Bonn. 
 
Strain   Description         
C57BL/6  Mice bear MHC-I haplotype H-2b 
PPARγfl/fl Mice with two loxP sequences flanking exon 1 and 2 of the PPARγ 
gene.105 
LysMCre   Mice, expressing a Cre-recombinase under the control of the 
lysosyme M promotor.106 
NestinCre  Mice, expressing a Cre-recombinase under the control of the nestin 
promotor and enhancer.107 
 
All mice were with C57BL/6 background. 
Crossing LysMCre or NestinCre mice with PPARγfl/fl mice results in specific ablation of 
PPARγ in cells of myeloid origin (LysM-PPARγKO mice) (e. g. microglia, monocytes, 
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macrophages and neutrophil granulocytes) or neuronal and glia cell precursors (Nestin-
PPARγKO mice) (e. g. astrocytes, neurons and oligodendrocytes). 
LysM-PPARγKO and Nestin-PPARγKO mice were born at the expected Mendelian ratio, 
were viable and fertile and developed normally. 
For Experiments, mice aged between 6 and 13 weeks were used. 
 
 
3.2 Methods 
 
3.2.1 Cell culture 
 
All cells were cultured in an incubator with a temperature of 37°C, a relative humidity of 
90%, and 5% CO2. 
 
3.2.1.1 Production of M-CSF for BM-M differentiation 
 
1.5 x 106 M-CSF transduced L929 cell were cultured in 30 ml BM-M medium for 3-4 days 
in 150 mm cell culture dishes. Then, supernatants were centrifuged at 1500 rpm for 10 min 
and afterwards filtered with 0.2 µm cellulose acetate membrane bottle top filters for 
sterilization. Supernatants were stored at -20°C. 
 
3.2.1.2 Isolation and culture of primary murine cells 
 
Preparation of BM-Ms 
Bone marrow was isolated from tibiae and femur. Therefore, mice were sacrificed, hind 
limps were cleaned with 70% (v/v) ethanol and tissue was relieved from tibiae and femur. 
Under sterile conditions, bones were flushed with 10 ml sterile PBS to isolate bone 
marrow. To get rid of small pieces of bone, cell suspension was filtered through a nylon 
sieve and afterwards centrifuged by 1500 rpm for 10 min. Cells from one mouse were split 
on three 10 cm Petri dishes in 10 ml BM-M medium, and cultured at 37 °C and 5 % CO2.  
Medium was chanced after four days. On day 7, cells were detached with 5 mM EDTA for 
10 min at 37 °C. 
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Preparation of mixed glial cultures 
Mixed glial cultures were prepared from postnatal mice on day 3-5. Therefore, mice were 
sacrificed and cleaned with 70% (v/v) ethanol. The cerebrum was isolated by carefully 
open the cranium. Then, meninges were removed with a tweezers. Then, the cerebrum was 
mechanically dissociated by use of a 5 ml pipette. Cell suspension was incubated for 
5 min, and to get rid of non dissociated particles, the supernatant was collected and 
centrifuged at 1500 rpm for 5 min. Then, supernatant was discharged and cells were seeded 
into 0.01% Poly-L-lysine pre-covered 75 cm2 cell-culture flasks. Medium was refreshed 
every week. 
 
Isolation of pMg 
Two weeks after preparation, pMg were harvested from mixed glial cultures by tapping the 
flasks vigorously. Afterwards, medium was refreshed. Cells were centrifuges at 1500 rpm 
for 10 min and seeded into 48-well plates for stimulation or for coculture. 
Cells from mixed glial cultures could be harvested again after a minimum of one week.  
 
Isolation of astrocytes 
Astrocytes were isolated from mixed glial cultures. Therefore, microglial cells were 
harvested as indicated above. By microscope, culture was checked for microglial cells. If 
the number of microglial cells compared to astrocytic cells is less than 5%, astrocytes were 
isolated from 75 cm2 cell-culture flasks by incubation with 10 ml Trypsin EDTA for 
10 min at 37°C. Trypsin EDTA was removed by centrifugation at 1500 rpm for 10 min. 
 
Isolation of T cells 
Mice were sacrificed by asphyxiation, cleaned with 70% (v/v) ethanol and spleens were 
isolated. Organs were dissociated by punching through a steel sieve. Afterwards, cells were 
centrifuged at 15000 rpm for 10 min. To gain a single-cell suspension, cells were filtered 
through a nylon sieve and centrifuged at 15000 rpm for 10 min. Then, cells were incubated 
with 20 µl CD4 MACS-beads (per spleen) in 500µl T cell medium (per spleen) for 15 min 
at 4 °C. Then, non-bonded beads were washed by centrifugation at 15000 rpm for 10 min. 
CD4+ T cells were separated from other cells, by immuno magnetic cell separation using 
auto-MACS. To get rid of the MACS-buffer, cells were washed, counted and 1 x 106 cells 
were seeded into a 48 well-plate in 1 ml T cell medium. To activate T cells, wells were 
pre-coatet with 4 µg/ml αCD3 and 4 µg/ml αCD28 in PBS for 1h at 37°C.  
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After three days, cells were harvested washed with medium, counted and cocultured with 
macrophages or microglia. 
 
Isolation of peritoneal cells 
Mice were sacrificed by asphyxiation and the body surface was cleaned with 70% (v/v) 
ethanol. Then, skin was removed from peritoneum and 8 ml ice cold PBS was injected into 
the abdomen with a 20 G needle and reabsorbed. 
 
3.2.1.3 In vitro stimulation of myeloid cells 
 
For in vitro stimulation, pMg were harvested and seeded into a 48 or 96 well-plate. 
Indicated concentrations of LPS and IFNγ were added for depicted hours. Then, 
supernatants were collected for quantification of NO by Griess assay and ROS by addition 
of H2DCFA. For intracellular quantification of TNFα by FACS or mRNA isolation for 
quantification of IL-6 and IL-12 mRNA levels by quantitative real-time RT-PCR, cells 
were harvested by incubation of 5mM EDTA for 10 min at 37°C. 
BM-Ms were stimulated in 48 or 96 well-plates with indicated concentrations of LPS and 
IFNγ for depicted hours. Supernatants were collected for NO determination by Griess 
assay and analysis of TNFα by Sandwich ELISA. For quantification of IL-6, IL-12 and 
CCL2, cells were harvested, mRNA was isolated and levels were analysed by quantitative 
real-time RT-PCR. 
 
3.2.1.4 Coculture experiments 
 
For coculture of astrocytes with BM-Ms or pMg, 8 x 105 astrocytes were cocultured with 
8 x 105 BM-Ms or pMg in 1 ml pMg medium in a 24 well-plate with or without 1 µg/ml 
LPS and 10 ng/ml IFNγ. If indicated, BM-M or pMg were pre-stimulated with 1 µg/ml 
LPS and 10 ng/ml IFNγ for 1 h. Afterwards, stimuli were washed out by centrifugation and 
cells were added to astrocytes. 
 
3.2.1.5 Determination of cell number by Neubauer counting chamber 
 
The cell suspension was diluted in 0.04 % trypane blue to discriminate between live and 
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dead cells. 10 µl of this suspension was applied to a Neubauer counting chamber and living 
cells were counted in all four large squares. The cell count was calculated using the 
following formula: 
Cell number / µl = counted viable cells / 4 (squares) x dilution x 104 
 
3.2.2 EAE experiments 
 
For EAE experiments, 6-8 week old female mice were immunized. Disease progress was 
analyzed daily. 
 
3.2.2.1 Immunization of EAE  
 
For active EAE immunization, MOG-CFA-mix was prepared by sonificating 50 µg 
MOG35-55 peptide and CFA including mycobacteria (ratio 1:1). 100 µl MOG-CFA-mix 
were injected into the base of tail. As the fluid is very viscous, this was done with a 20 G 
needle. On day 0 and day 2 after immunization, 200 ng PTX (in 200 µl) were injected i.p.. 
 
3.2.2.2 Adoptive transfer EAE 
 
For adoptive transfer EAE, T cells were primed in PPARγfl/fl donor mice, isolated and 
injected into LysM-PPARγWT or LysM-PPARγKO recipients. Therefore, donors were 
immunized with 50 µg MOG35-55 peptide and CFA s.c. in the left flank (nearby the spleen). 
Donors did not receive PTX injections. After 10 days, spleens were isolated. Under sterile 
conditions, spleens were dissociated by a steel sieve. To get a single-cell-suspension, cells 
were pass through a nylon filter. Then, cells were centrifuged, and mononuclear cells were 
counted. 20 ng/ ml MOG35-55 peptide was added to 2 x 107 cells and seeded into a 6 well-
plate at a volume of 4 ml T cell medium. 
After 3 days, cells were harvested and washed twice with PBS. Afterwards, cells were 
resuspended in PBS and counted in a Neubauer counting chamber. 1.6 x 107 cells were 
injected i.p. into recipient mice. On days 0 and 2 after cell injection, mice obtained 
200 ng PTX (in 200 µl) by i.p. injection. 
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3.2.2.3 Analysis of disease progression 
 
The clinical assessment of diseased mice was performed daily using the following scale:  
- 0: no paralysis  
- 1: limp tail 
- 2: ataxia or unilateral hind limb paresis 
- 3: severe unilateral or weak bilateral hind limb paresis 
- 4: severe bilateral hind limb paresis 
- 5: complete bilateral hind limb plegia 
- 6: complete bilateral hind limb plegia and partial fore limb paresis 
- 7: severe tetraparesis / plegia 
- 8: moribund / dead animals.  
 
3.2.2.4 Isolation of CNS-mononuclear cells from EAE-diseased mice 
 
At indicated timepoints, mice were sacrificed by i.p. injection of a lethal dose of the 
anesthesia Tribromoethanol (Avertin). Then, aorta was dissected and bloodstream was 
perfused with 50 ml brain perfusion buffer. Afterwards, brain and spinal cord were 
carefully isolated. Under sterile conditions, organs were fragmented and incubated in 10 ml 
GBSS + 0.5% (v/v) collagenase at 37°C for 30 min. Then, cells were dissociated through a 
steel sieve and washed with PBS + 1% (v/v) FCS. Mononuclear cells were isolated from 
suspension by a percoll gradient. Therefore, cells were suspended in 30% percoll (in PBS) 
and underlayed with 37 % and 70 % percoll. Gradient was centrifuged at 2000 rpm for 
30 min at 4°C (without brake). Both interphases were taken of and cells were washed twice 
with PBS + 1% (v/v) FCS (1500 rpm; 10 min). For flow cytometric analysis of 
macrophages and microglia, cells were resuspended in FACS buffer. For examination of 
T cell activation, cells were resuspended in medium. 
 
3.2.2.5 Isolation of T cells from draining lymph nodes from EAE-diseased mice 
 
Mice were sacrificed and inguinal lymph nodes (LN) were isolated. Under sterile 
conditions, LN were dissected and washed twice with PBS + 1% (v/v) FCS. 
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3.2.2.6 Analysis of T cell activation ex vivo 
 
For intracellular analysis of IFNγ and IL-17-production by FACS, T cells were isolated 
from brain and spinal cord or draining LN of EAE-diseased mice. 4 x 105 cells were 
seeded into a 96 well-plate (round bottom) for 4 h. For restimulation of T cells, 5 ng/ ml 
PMA and 200 ng/ ml Ionomycin were added. In order to accumulate cytokines, monensin 
and brefeldin A (inhibiting cytokine secretion; 1 µl per ml medium) were also added. 
 
3.2.2.7 Immunohistochemistry 
 
The laboratory of Prof. M. Prinz, Freiburg, kindly performed immunohistochemical 
analysis of the CNS. 
For histological staining of the CNS, mice were anesthetized with a lethal dose of 
Tribromoethanol (Avertin) on day 35 after EAE immunization. The CNS was perfused 
with 25 ml brain perfusion buffer and afterwards fixed by perfusion with 25 ml 4 % PFA. 
Then, brain and spinal cord were carefully isolated and stored in 4 % PFA. 
Immunohistochemistry of the spinal cord was kindly performed by Dr. Ildiko Dunay and 
Prof. Dr. Marco Prinz (Department of Neuropathology, University of Freiburg, Germany) 
as described108. Degree of demyelination was assessed by staining myelin with luxol fast 
blue (LFB) followed by incubation in Schiff reagent, staining demyelinated areas in pink. 
The percentage of demyelinated areas related to total area was quantified using Cell 
Analysis Software.  
For detection of axonal damage, deposits of APP were counted after staining sections for 
APP. To detect CNS-resident microglia and infiltrating macrophages and T cells, 
immunohistochemical staining of MAC-3 and CD3 was performed. Five mice per group 
and three sections per animal were analyzed for quantification of demyelination, APP 
deposits and immune cell infiltration, which are indicated as numbers per total CNS area 
per mm2. 
 
3.2.2.8 Monocyte transfer experiments 
 
Inflammatory monocytes were isolated from the bone marrow of LysM-PPARγKO and 
LysM-PPARγWT mice, respectively, using a biotinylated antibody for CD115 and biotin-
MACS-beads. Then, 1 x 107 CD115+ PPARγKO or PPARγWT monocytes were injected i.v. 
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into EAE diseased mice. Transfer of monocytes was performed on days 12, 14, 16, and 19 
after immunization. To get enough cells, monocytes were isolated from 15 LysM-
PPARγKO and 15 LysM-PPARγWT mice at each time point. 
 
3.2.2.9 Monocyte depletion during EAE 
 
During EAE, depletion of CCR2+ inflammatory monocytes in LysM-PPARγKO and LysM-
PPARγWT mice was performed using the anti-CCR2 antibody MC-21. 200 µl with 20 µg of 
the antibody were injected i.p. into diseased mice every 24 h on days 13-17 after EAE-
immunzation. Depletion of the cells was controlled in the blood by FACS-analysis 8 h 
after the first injection. For negative control, isotype control of the antibody was injected 
into control mice. 
 
 
3.2.3 Magnetic-activated cell sorting (MACS) 
 
Prior to the isolation of cells by MACS-beads separation, spleens for isolation of DCs were 
perfused with 5 ml GBSS +0.5% (v/v) collagenase and incubated for 20 min at 37°C.  
For isolation of macrophages, DCs, T cells, or B cells from the spleen by magnetic cell 
separation, spleens were minced by using a steel sieve. Afterwards, cell suspension was 
centrifuged for 10 min at 1500 rpm at 4°C and pellet was re-suspended in 500µl of ice-cold 
MACS-buffer. Then, antibody coated MACS-beads were added (15µl per spleen for DC 
separation and 25µl per spleen for separation of macrophages, T cells or B cells). After 15 
minutes of incubation at 4°C, 50 ml of ice-cold MACS-buffer were added and the cell 
suspension was centrifuged at 1500 rpm for 10 min at 4°C. Afterwards, cell suspension 
was filtered through a nylon sieve and cell separation was performed with the 
autoMACS™ separator using program ‘POSSEL’. 
 
3.2.4 Flow Cytometry 
 
For all flow cytometry examinations, cells were stained in 96 well-plate (round bottom) 
and measurements were performed with FACS Canto II from BD Bioscience was used. 
Antibodies for surface marker or intracellular staining were diluted in buffer as follows: 
 
Materials and Methods 
   28 
Antigen  Conjugate  Dilution 
CD4   PE   1:100  
                       Pacific blue  1:200  
CD8a   PE   1:100  
CD11b  APC   1:100  
CD40   PE   1:100  
CD45   Pacific blue  1:200  
   FITC   1:100  
IFNγ   PE   1:100  
IL-17A  APC   1:100  
   PE   1:100  
Ly-6C   PerCP-Cy5.5  1:300  
Ly-6G   APC   1:300  
   FITC   1:100  
MHC-II  PE   1:100  
TNFα   PE   1:100  
 
3.2.4.1 Surface marker staining 
 
For surface marker staining, cells were washed with FACS buffer. Cells were resuspended 
in FACS buffer containing 2.4G2 FcBlock and the appropriate diluted antibody. Cells were 
incubated for 15 min on ice and protected from light. Then, 100 ml FACS buffer were 
added and cells were centrifuged for 2 min at 1600 rpm to wash away unconjugated 
antibodies.  
 
3.2.4.2 Intracellular staining of cytokines 
 
Intracellular cytokine staining was performed by using BD Cytofix/Cytoperm fixation and 
permeabilisation solutions. In order to accumulate cytokines, monensin and brefeldin A 
(inhibiting cytokine secretion; 1 µl per ml medium) were added to cells 4 h prior 
intracellular staining of cytokines. Then, after surface markers staining cells were 
resuspended and fixed in 100 µl of BD Cytofix/Cytoperm fixation solution for 20 min on 
ice and protected from light. Cells were washed twice with 100 µl BD Cytofix/Cytoperm 
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permeabilisation solution (diluted 1:10 in A. bidest) (1600 rpm, 5 min, 4°C). Then, 
staining was done with 50 µl BD Cytofix/Cytoperm permeabilisation solution containing 
2.4G2 FcBlock and the appropriate diluted antibody for 30 min on ice and cells were 
protected from light. Afterwards, cells were washed twice with 100 µl BD 
Cytofix/Cytoperm permeabilisation solution (diluted 1:10 in A. bidest) (1600 rpm, 5 min, 
4°C) and cells were resuspended in FACS buffer for analysis. 
 
3.2.4.3 Determination of absolute cell number by flow cytometry 
 
Prior to FACS analysis, CountBright Absolute Counting Beads micropsheres were added 
to cells. Therefore, microspheres were vortexed and approx. 2000 beads were added right 
before FACS measurement. During measurement, cells as well as beads were counted by 
the system. Afterwards, absolute cell number per vial was calculated by following formula: 
 
Total cell number = (counted cells / counted beads) x 2000 
 
3.2.4.4 FACS-sorting 
 
For quantitative real-time RT-PCR of microglia and macrophages in the CNS of EAE 
diseased LysM-PPARγWT or LysM-PPARγKO mice, cells were isolated from the CNS at 
day 21 after immunization as indicated at 3.2.2.4 (Isolation of CNS cells from EAE-
diseased mice). Then, surface markers CD11b and CD45 were stained with fluorescent 
labeled antibodies for 10 min at 4°C and CD11b+CD45+ cells were sorted using a BD 
FACS DiVa. 
 
3.2.5 Evaluation of mRNA-levels  
 
3.2.5.1 Isolation of mRNA from cells suspension 
 
mRNA was isolated from pMg or BM-Ms with RNeasy Mini Kit: 
Cells were washed with PBS and resuspended in 350 µl RLT buffer with 10 µl / ml β-ME. 
Cells were homogenized by passing five times through a 20 G needle using a 1 ml syringe. 
Then, 350 µl 70% ethanol was added to cells and lysate was applied to RNeasy spin 
Materials and Methods 
   30 
columns and centrifuged at 11000 rpm for 15 sec. The flow-trough was discarded. Then 
RNA was washed with 700 µl of the buffer RW1 (11000 rpm, 15 sec), 500 µl RPE buffer 
(1100 rpm, 15 sec), and 500 µl RPE buffer (1100 rpm, 2 min). Afterwards, columns were 
dried by centrifugation (13000 rpm, 1 min). Then, 30 µl nuclease-free water was incubated 
on columns for 1 min and for eluation of RNA, columns were centrifuged at 11000 rpm for 
1 min. The concentration of m-RNA was evaluated by Nanodrop and stored at -80°C. 
 
3.2.5.2 Isolation of mRNA from CNS-tissue 
 
For mRNA isolation from CNS-derived tissue, a part from the cervical spinal cord was 
dissected (approx. 50-100 mg) and stored in RNAlater at -20°C until isolation with 
TriReagent. Then, 1 ml TriReagent was added to tissue and suspension was made using an 
ultra-turrax. After incubation for 5 min at RT, suspension was centrifuged (13000 rpm, 
5 min, 4°C). Supernatants were transferred into a new tube, incubated with 100 µl BCP for 
10 min at RT and centrifuged (13000 rpm, 15 min, 4°C). Aqueous phase was transferred 
into a new tube, mixed with 500 µl isopropyl alcohol and incubated for 10 min at RT. 
mRNA was centrifuged (13000 rpm, 8 min 4°C), supernatants were discarded and pellet 
was washed twice with 75% cold ethanol (-20°C) (10000 rpm, 5 min, 4°C). After drying 
the pellet was resuspended in 50 µl DEPC-treated water. mRNA-concentration was 
evaluated by Nanodrop and stored at -80°C. 
 
3.2.5.3 Reverse transcription 
 
mRNA was transcribed into cDNA by reverse transcriptase using SuperScript III. 
Therefore, 8 µl of the mRNA, containing 1000 ng, was mixed with 10 µl 2 x RT buffer and 
2 µl RT Enzyme Mix. Then, mixture was incubated for 10 min at RT and PCR program 
was proceeded by Thermocycler at 50°C for 30 min and afterwards 85°C for 5 min. Then 
1 µl of the E. coli RNase H was added into the tubes followed by an incubation at 37°C for 
20 min. 
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3.2.5.4 Quantitative real-time RT-PCR 
 
Real-time RT-PCR was performed in an Abi Prism 7900 HT thermocycler. Therefore the 
PCR reaction mixture was prepared with PowerSYBR Green PCR Master Mix (for 
primers) or TaqMan Gene Expression Master Mix (for FAM-labeled TaqMan probes) in 
triplicates. 
 
 
PCR reaction mix component TaqMan Gene Expression Power SYBR Green 
Taq Man Gene Expression Assay 0,5 µl - 
SYBR Green primers (forw and rev) - 0,5 µl (each) 
Taq Man Gene Expression Master 
Mix 
5 µl - 
Power SYBR Green Master Mix - 5 µl 
cDNA template 1 µl 1 µl 
Nuclease free water 3,5 µl 3 µl 
 
Amplification of cDNA was carried out for 40 cycles. Quantification of the relative data 
was examined using the ΔΔCT method, normalizing data to GAPDH according to 
manufacturer’s protocol (described in the User Bulletin 2 of the Abi Prism). 
 
3.2.6 Measurement of cytokine concentration by Sandwich-ELISA 
 
For cytokine-detection in supernatants, 96-well ELISA plates were coated with 50 µl of the 
capture antibody diluted in coating buffer at 4°C over night. 
Then, plates were washed five times with washing buffer and plate was incubated with 
100 µl blocking buffer to overcome unspecific binding for 30 min at room temperature 
(RT). Afterwards, plates were washed five times with washing buffer and 50 µl of the 
samples were added to the wells and incubated over night at 4°C. For quantitative analysis, 
a titration of the particular cytokine was added among the 96 well-plate as well as a 
negative control. 
Afterwards, plates were washed five times with washing buffer and 50 µl of the secondary, 
biotin-labelled antibody (detection antibody) diluted in blocking buffer was added to the 
plate for 2 h at RT. After washing the plate five times with washing buffer, 50 µl of the 
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horseradish peroxidase streptavidin conjugate (diluted 1:1000 in PBS) was added for 
30 min at 4°C. Plates were washed five times and 50 µl TMB substrate was added into the 
wells and the optical density (OD) of the samples were analyzed by ELISA reader at a 
wavelength of 650 nm. When the OD of the highest concentrated positive control was 1, 
by adding 25 µl of the stop solution to the substrate immediately reaction was stopped and 
plates were analyzed at o wavelength of 450 nm. The concentration of cytokine in the 
samples was calculated by the computer program SOFTmax pro and indicated as pg/ml, 
ng/ml, or µg/ml. 
 
Cytokine  Dilution of 1st antibody  Dilution of 2nd antibody 
TNFα     1:500     1:500  
CCL2     1:250     1:250 
 
3.2.7 Determination of ROS 
 
To analyze the production of ROS by pMg, cells were seeded into a 96-well cell-culture 
plate. When cells attached, medium was discarded and cells were incubated with 100 µl of 
the H2DCFA solution (20 mM in PBS) at 37°C for 5 min. Afterwards, emission was 
excited with 485 nm and determined at 530 nm in a pre-heated (37°C) ELISA reader. Cells 
incubated without the indicator H2DCFA served as a negative control. 
 
3.2.8 Griess assay for nitrite determination 
 
Determination of nitrite was done with Griess assay purchased from Molecular probes. 
For analysis, equal volumes of component A and B were mixed freshly (20 µl per sample). 
Then, 20 µl of this mixture (Griess reagent) and 130 µl deionised water were added into a 
96-well ELISA microtiter plate. 150 µl of the sample to be analyzed or different 
concentrations of the sodium nitrite solution (component 3) were incubated with griess 
reagent in the wells at RT. For negative control 150 µl of the deionise water was used. 
After 30 min, reaction was analyzed by ELISA reader at a wavelength of 548 nm. 
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3.2.9 Determination of PPARγ-ablation by PCR 
 
PPARγ-ablation was analyzed in cells derived from LysM-PPARγKO or LysM-PPARγWT 
mice. The following cells were isolated by MACS from spleens using indicated MACS-
beads: 
 
Cells    MACS-beads   
Macrophages   CD11b 
DCs    CD11c  
B cells    CD19 
CD4+ T cells   CD4 
CD8+ T cells   CD8 
 
Peritoneal macrophages were isolated from the peritoneum as indicated in section 3.2.1.2. 
For isolation of peritoneal neutrophilic cells, 2 ml thioglycollate was injected i.p. 3 days 
prior to isolation. 
Then, mRNA was isolated with RNeasy Mini Kit and transcribed into cDNA using 
Superscript III. 10 µl of the transcribed cDNA was used for PCR with following 
components purchased from invitrogen: 
280 µl  H2O 
50 µl  10 x buffer 
20 µl  50mM MgCl2 
20 µl dNTPs 
10 µl primer forward 
10 µl primer reverse 
10 µl TaqPolymerase 
 
 
PCR program was performed using following steps: 
94°C 5 min 
94°C 30 sec 
60°C 45 sec  39 cycles 
72°C 45 sec 
72°C 10 min 
4°C  
 
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The analysis of PCR products was validated by agarose gel electrophoresis using a 2% 
agarose gel. 
 
3.2.10 Statistics 
 
Results are depicted as mean +/- standard error of the mean (SEM). Statistic significances 
were calculated by unpaired two-tailed Student’s t test. p values of 0.01 to 0.05 were 
considered as significant (*), p values of 0.001 to 0.01 as highly significant (**), and p 
values of < 0.001 as extremely significant (***). 
The number of independent experiments are indicated in the legend. 
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4 Results 
 
4.1 Role of PPARγ  in myeloid cells during CNS-inflammation 
 
The importance of CNS-invading auto-reactive CD4+ T cells, primed in the periphery and 
initiating EAE, has been sufficiently documented27,30,109-112. However, recent data indicate 
that the effector mechanisms leading to progression of inflammation and demyelination 
within the CNS are mediated by other cell types, especially infiltrating macrophages and 
resident microglia113,114. Activation of PPARγ in myeloid cells has been proven to impair 
expression of pro-inflammatory mediators in these cells72,75,115. Therefore, the question 
arose if PPARγ in microglia and macrophages might be a promising regulator during 
inflammatory diseases like EAE. 
 
4.1.1 PPARγ  in myeloid cells controls the effector phase of EAE 
 
This thesis adressed the role of the anti-inflammatory transcription factor PPARγ in 
myeloid cells during CNS inflammation. To this end, mice with a conditional  knock-out of 
PPARγ in LysM expressing cells, encompassing monocytes / macrophages, microglia, 
granulocytes, and partially in CD11c+ splenic DCs106 (LysM-PPARγKO mice) were utilized.  
PPARγ cDNA analyzed by real-time RT-PCR in various cell populations showed a 
truncated 300bp fragment of PPARγ cDNA in cells expressing LysM. In contrast, non-
myeloid cells showed full-length 700bp wildtype PPARγ cDNA (Figure 1a). As shown in 
Figure 1a, LysM-PPARγKO mice lack PPARγ in microglia, monocytes / macrophages, and 
neutrophils, whereas PPARγ-expression was only partially affected in CD11c+ splenic 
cells, but not in T cells and B cells. 
To analyze the role of PPARγ in myeloid cells during CNS-inflammation, EAE, the animal 
model of MS, was used. Therefore, active MOG-EAE was induced in LysM-PPARγKO 
mice and their wildtype littermates by immunization with MOG35-55 peptide in complete 
Freund’s adjuvant (CFA) and Pertussis toxin, which was injected together with        
MOG35-55-CFA and in addition on day two after immunization. Disease progress was 
monitored daily. (EAE-experiment was performed with Stephanie Hucke.) 
Results 
   36 
Importantly, during the effector phase of EAE the course of disease was significantly 
aggravated in LysM-PPARγKO mice compared to their wildtype littermates (LysM-
PPARγWT) beginning at day 15 after immunization (Figure 1b). In contrast, alterations in 
course of disease were not observed during the T cell-dependent induction phase (days 1 to 
14) (Figure 1b).  
To address the question whether the aggravated disease course in LysM-PPARγKO mice 
was accompanied by enhanced inflammation and tissue damage, spinal cords of either 
LysM-PPARγKO mice or wildtype littermates were histopathologically analyzed during the 
effector phase of EAE on day 35 after immunization. As shown in Figure 1c, both 
demyelination and axonal damage were increased in the spinal cord of LysM-PPARγKO 
mice compared to LysM-PPARγWT controls. Additionally, infiltration of T cells and 
macrophages was significantly increased in LysM-PPARγKO mice compared to the 
wildtype littermates at that point of time (Figure 1d). 
 
 
 
Figure 1     PPARγ in myeloid cells controls the effector phase of EAE (Experiments 
performed with Stephanie Hucke) 
(a) PPARγ ablation in myeloid cells: RT-PCR analysis of mRNA isolated from primary microglia, 
CD11b+ splenic cells, peritoneal macrophages, neutrophil granulocytes, CD11c+ splenic cells, 
T cells and B cells derived from LysM-PPARγKO (KO) mice or their wildtype (WT) littermates. 
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Expression of Cre-recombinase in myeloid cells results in a specific ablation of PPARγ cDNA 
(300 bp fragment), in contrast to wildtype cDNA (700 bp). (b) Mean clinical score of EAE-
diseased LysM-PPARγWT (n=12) or LysM-PPARγKO (n=13) mice. Active EAE was induced by 
immunization with MOG35-55 and disease was monitored daily. Mean clinical score ± SEM of two 
representatives out of five independent experiments is shown. (c+d) Histopathological analysis 
(left) and quantification (right) of (c) structural damage: demyelination (luxol fast blue (LFB)), 
axonal damage (amyloid precursor protein (APP) (n=5 per group), (d) and CNS-infiltration by 
macrophages / microglia (MAC-3) and T cells (CD3) (n=5). 
Data are shown as mean ± SEM. * p<0.05; ** p<0.01. 
 
These results show that lack of PPARγ in myeloid cells leads to an aggravated disease 
course during the effector phase of EAE, accompanied by enhanced immune cell 
infiltration and tissue damage.  
To further analyze the inflammatory milieu within the CNS during the effector phase, 
mRNA levels of several pro-inflammatory mediators were evaluated by quantitative real-
time RT-PCR.  
Compared to non-diseased mice, mRNA levels of pro-inflammatory cytokines like IL-1β, 
IL-12, TNFα, and IFNγ were increased in diseased LysM-PPARγWT mice, and were further 
augmented in LysM-PPARγKO EAE mice (Figure 2a). Additionally, mRNA levels of iNOS 
were significantly augmented in LysM-PPARγKO mice. Moreover, as shown in Figure 2b, 
mRNA levels of the chemokines CCL2, CCL3, CCL5, and CXCL10, were three- to seven-
fold higher in LysM-PPARγKO mice compared to wildtype littermates. 
 
 
 
Figure 2 PPARγ in myeloid cells controls the inflammatory milieu within the CNS 
during the effector phase of EAE 
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(a-b) mRNA levels of (a) inflammatory cytokines, iNOS, (b) and chemokines in cervical spinal 
cord of LysM-PPARγKO (KO) mice or LysM-PPARγWT (WT) EAE mice (n=10 per group) 
quantified by quantitative real-time RT-PCR. mRNA was isolated from tissue on day 21 after 
immunization. Data are shown as n-fold induction compared to healthy controls (n=3) and were 
normalized to endogenous GAPDH expression.  
Data expressed as mean ±SEM. * p<0.05; ** p<0.01. 
 
To analyze whether PPARγ modulates the activation status of myeloid cells during EAE 
per se, mRNA levels of IL-1β in microglia and macrophages isolated from the CNS of 
EAE-diseased LysM-PPARγWT or LysM-PPARγKO mice were examined. 
Although the alteration did not reach statistical significance, enhanced levels of IL-1β 
mRNA were observed in macrophages and microglia from LysM-PPARγKO mice 
compared to wildtype littermates (Figure 3).  
 
 
 
Figure 3 PPARγ controls IL-1β-expression in myeloid cells during the effector phase of 
EAE  
mRNA-level of IL-1β in macrophages and microglia from LysM-PPARγWT (WT) (n=4) or LysM-
PPARγKO (KO) (n=3) EAE mice. Cells were isolated by fluorescence-activated cell sorting, based 
on their CD11b+CD45+ expression. Levels were quantified by quantitative real-time RT-PCR, 
normalized to endogenous GAPDH-expression and shown as n-fold induction compared to 
unstimulated BM-Ms.  
 
In summary, lack of PPARγ in myeloid cells resulted in an aggravated disease course 
during the effector phase of EAE, accompanied by an increased release of inflammatory 
and chemoattractant mediators in the CNS. Thus, these data identify PPARγ in myeloid 
cells as a crucial regulator for CNS inflammation during EAE pathology. 
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4.1.2 PPARγ  controls immunological activation in myeloid cells during 
the effector phase of EAE 
 
So far, the in vivo findings revealed that PPARγ in myeloid cells effects demyelination, 
axonal damage, and inflammation during the effector phase of EAE.  
As T cells play an important role in EAE-pathology109,110 and expression of CD40 and 
MHC-II molecules on the surface of microglia and macrophages are important for 
interacting with encephalitogenic T cells during EAE116-118, the question arose, if PPARγ in 
myeloid cells might also influence the interaction with auto-reactive encephalitogenic 
T cells, which then might result in altered T cell-activation.  CNS mononuclear cells were 
isolated from LysM-PPARγKO and LysM-PPARγWT mice on day 21 after EAE 
immunization and the expression of CD40 and MHC-II on macrophages and microglia was 
analyzed by flow cytometry.  
Both cell-types are CD11b+, but can be distinguished by their different expression of the 
surface-molecules CD45 and Ly-6C: Macrophages are characterized by high levels of 
CD45 and Ly-6C (CD45hiLy-6C+), whereas microglia are characterized by a low to 
intermediate expression of CD45 and Ly-6C (CD45loLy-6Clo) (Figure 4a).  
As shown in Figure 4b, both, infiltrating macrophages and microglia derived from LysM-
PPARγKO mice, showed significantly increased levels of the surface marker CD40 
compared to their wildtype control on day 21 after EAE immunization (Figure 4c). Further, 
increased levels of MHC-II surface expression on macrophages and microglia within the 
CNS of LysM-PPARγKO mice compared to their wildtype control were observed 
(Figure 4d). In addition, the percentage of MHC-II-expressing macrophages and microglia 
was enhanced in LysM-PPARγKO mice compared to LysM-PPARγWT mice (Figure 4e). 
Moreover, flow cytometric analysis revealed a two-fold increase in absolute cell numbers 
of both, macrophages and microglia, in LysM-PPARγKO compared to wildtype littermates 
at that time point (Figure 4f). 
In conclusion, the expression of CD40 and MHC-II, molecules that are important for 
interaction with auto-reactive encephalitogenic T cells, was increased in LysM-PPARγKO 
EAE mice during the effector phase of EAE compared to wildtype littermates. This 
indicates that PPARγ modulates the activation status in microglia and macrophages during 
the effector phase of EAE. 
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Figure 4 PPARγ controls the immunological activation in myeloid cells during the 
effector phase of EAE  
Analysis of macrophages and microglial cells within the CNS during the effector phase of EAE. 
CNS-mononuclear cells were isolated from brain and spinal cord of LysM-PPARγWT (WT) or 
LysM-PPARγKO (KO) EAE mice on day 21 after immunization. (a) Classification of CD11b+ 
macrophages and microglial cells based on the expression of CD45 and Ly-6C. (b+d) Expression 
of surface molecules (b) CD40 (n=12) and (d) MHC-II (n=9) was analyzed by flow cytometry. 
Histograms depict unstained control (tinted) and CD40- or MHC-II-specific antibody (line). Mean 
fluorescence intensity (MFI) ± SEM is indicated in graphs. (c+e) Percentage of CD40- (c) (n=12) 
or MHC-II- (e) (n=9) positive macrophages or microglial cells within the CNS. Graphs depict 
mean percentage ± SEM. (f) Absolute cell numbers of macrophages and microglia on day 21 after 
EAE-immunization. Cells were quantified by flow cytometry using fluorescently labeled beads and 
indicated as mean ± SEM; n=5 per group. * p<0.05. 
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4.1.3 PPARγ  in myeloid cells does not affect T cell priming during the 
induction phase of EAE 
 
It is known, that activation of PPARγ in APCs impairs T cell priming77,119. Hence, it is 
arguable, whether the observed aggravated disease course during the effector phase of 
EAE in LysM-PPARγKO mice compared to wildtype controls (Figure 1) might be a 
consequence of PPARγ-ablation in peripheral macrophages affecting initial T cell priming 
in the periphery.  
To investigate a potential influence of PPARγ in peripheral myeloid cells (e.g. 
macrophages) on T cell priming during development of EAE, MOG-specific CD4+ T cell 
responses were characterized at different time points.  
To this end, T cells from the draining lymph nodes or the CNS from either LysM-
PPARγKO EAE mice or wildtype control mice were isolated and MOG-specific IFNγ- and 
IL-17A-responses were assessed on days 7 or 14 (induction phase) and on days 21 and 27 
(effector phase).  
However, an increase in MOG-specific IFNγ-production was not observed in the draining 
lymph nodes from LysM-PPARγKO mice (Figure 5a). Furthermore, on days 7 and 14, the 
percentage of IL-17A-producing T cells was not significantly different in the draining 
lymph nodes. Moreover, no differences in the percentages of IFNγ- or IL-17A-producing 
CD4+ T cells were found in the CNS of LysM-PPARγKO mice compared to LysM-
PPARγWT mice on day 14 or 27 after immunization, respectively (Figure 5b). Likewise, 
CD8+ T cell responses were not altered on day 27 after immunization (Figure 5c). 
To further exclude an effect of PPARγ on the immunological activation in peripheral APCs 
like macrophages and therefore on T cell priming during the induction phase of EAE, 
MOG-activated T cells from immunized wildtype mice, were adoptively transferred into 
either wildtype recipients or LysM-PPARγKO mice.  
Importantly, the course of disease was significantly aggravated during the effector phase in 
LysM-PPARγKO mice compared to LysM-PPARγWT mice during adoptive transfer EAE, 
although this difference was not as pronounced as during active MOG-EAE (Figure 5d). 
This difference was observed in three independent experiments. 
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Figure 5 PPARγ in myeloid cells does not influence activation of T cell during EAE 
(a-c) Analysis of T cells from draining lymph nodes or CNS from LysM-PPARγWT (WT) or LysM-
PPARγKO (KO) EAE mice. At indicated time points, mononuclear cells were isolated from (a) 
draining lymph nodes (drLN) or (b+c) the CNS, and (a+b) CD4+ or (c) CD8+ T cells were analyzed 
for IFNγ- or IL-17A-expression by flow cytometry (n=5 per timepoint). Graphs depict the mean 
percentage ± SEM. (d) Mean clinical score of adoptive transfer EAE: MOG35-55-reactive T cells 
were primed in wildtype mice, restimulated in vitro and transferred into either LysM-PPARγWT 
(n=6) or LysM-PPARγKO (n=7) mice.  
Graph shows mean clinical score ± SEM. * p<0.05; ** p<0.01. 
 
In conclusion, these data corroborate the hypothesis that PPARγ in myeloid cells regulates 
local CNS-inflammation during the effector phase of EAE, but does not significantly affect 
T cell priming or differentiation during the initial priming phase.  
 
4.1.4 PPARγ-ablation in astrocytes, neurons and oligodendrocytes 
does not affect disease score during EAE 
 
So far, these data reveal an influence of PPARγ in myeloid cells on CNS inflammation 
during the effector phase of EAE. As other CNS resident cells like astrocytes, neurons and 
oligodendrocytes also play a role in CNS inflammation6,120, an effect of PPARγ on these 
CNS resident cells was examined during CNS inflammation. 
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To this end, mice with a conditional knock-out of PPARγ in CNS resident cells were 
employed (Nestin-PPARγKO).  
As shown in Figure 6a, astrocytes derived from Nestin-PPARγKO mice, but not microglia, 
exhibited PPARγ-ablation (Figure 6a), characterized by a truncated 300bp fragment of 
PPARγ cDNA, in contrast to the full-length 700bp wildtype cDNA. 
To analyze the role of PPARγ in astrocytes and neuronal cells during CNS-inflammation, 
Nestin-PPARγKO mice and wildtype littermates were immunized with MOG35-55 peptide 
and the course of EAE was determined.  
Upon MOG-immunization, differences in disease score were not observed in Nestin-
PPARγKO mice compared to wildtype control littermates (Figure 6b), indicating that 
PPARγ is not a potent regulator in CNS resident astrocytes and neuronal cells during CNS 
inflammation. 
 
 
 
Figure 6  PPARγ ablation in CNS resident cells does not affect disease score during EAE 
Nestin-Cre mice were crossed with PPARγfl/fl mice, resulting in specific PPARγ ablation in CNS 
resident cells. (a) RT-PCR analysis of mRNA from primary astrocytes and primary microglia. 
Expression of Cre-recombinase in myeloid cells results in a specific ablation of PPARγ cDNA 
(300 bp fragment), in contrast to wildtype cDNA (700 bp). (b) Mean clinical score of EAE-
diseased Nestin-PPARγWT (n=9) or Nestin-PPARγKO (n=6) mice. MOG35-55-EAE was induced by 
active immunization and mice were clinically monitored daily. Figure depicts mean clinical score ± 
SEM of one representative experiments out of four. 
 
4.1.5 PPARγ  controls activation of myeloid cells in vitro 
 
So far, the in vivo findings revealed an influence of PPARγ in myeloid cells on local CNS-
inflammation during the course of EAE (Figure 1 and 2). To further characterize the effect 
of PPARγ on the innate immune response in myeloid cells in vitro, levels of cytokines, 
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chemokines, and neurotoxic mediators were analyzed in bone marrow-derived 
macrophages (BM-Ms) and primary microglia (pMg) derived from either LysM-PPARγKO 
or LysM-PPARγWT mice. 
Upon stimulation, PPARγKO BM-Ms exhibited a significant 1.5-fold increase in nitrite-
release compared to wildtype BM-Ms. In addition, levels of TNFα were increased 1.5-fold 
in the supernatants of stimulated BM-Ms derived from PPARγKO mice compared to 
PPARγWT BM-Ms. Moreover, analysis of mRNA levels of inflammatory cytokines like  
IL-6 and IL-12 revealed an 1.5- and 2-fold increase, respectively, in PPARγKO 
macrophages compared to wildtype macrophages. Furthermore, CCL2 levels were 3-fold 
higher in PPARγKO BM-Ms compared to wildtype macrophages (Figure 7a).  
Increased levels of neurotoxic mediators and inflammatory cytokines were also observed 
in primary microglial cells (pMg) isolated from neonatal LysM-PPARγKO and wildtype 
littermate pups: Upon stimulation with LPS and IFNγ, significantly increased levels of 
nitrite in the supernatants of PPARγKO pMg compared to wildtype pMg were detected. 
Additionally, a significant increase in ROS was determined in PPARγKO pMg compared to 
wildtype pMg as well as an elevation in the percentage of TNFα+ pMg. mRNA-levels of 
the inflammatory cytokines IL-6 and IL-12 were 2-fold higher in PPARγKO pMg compared 
to wildtype pMg (Figure 7b). 
 
 
 
Figure 7 PPARγ regulates innate immune responses in myeloid cells  
(a) BM-Ms from PPARγKO or PPARγWT mice were stimulated (stim) for determination of NO-
production by Griess assay (100 ng/ml LPS and 10 ng/ml IFNγ, 48 h) and TNFα-release by ELISA 
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(100 ng/ml LPS, 24h). Control cells were not stimulated (w/o stim). mRNA-levels of IL-6, IL-12, 
and CCL2 were quantified by real-time RT-PCR after stimulation (1 µg/ml LPS and 5 pg/ml IFNγ, 
6 h). Data were normalized to endogenous GAPDH expression and shown as n-fold induction 
compared to unstimulated control. (b) PPARγKO or PPARγWT pMg were stimulated for 
quantification of NO- (1 µg/ml LPS and 10 ng/ml IFNγ, 48 h), or ROS-production (10 µg/ml LPS, 
24h). Induction of ROS is expressed as fold chance in relative light units compared to unstimulated 
control. Percentage of TNFα+ pMg was intracellularly analyzed by flow cytometry after 
stimulation (1 µg/ml LPS and 5 pg/ml IFNγ, 4 h) in the presence of monensin and brefeldin A. 
Stimulation of pMg for mRNA-detection and -quantification was determined as indicated for      
BM-Ms (7a). 
Data are expressed as mean ± SEM (n=3). * p<0.05; ** p<0.01; *** p<0.001 
 
In conclusion, PPARγ-ablated macrophages and microglial cells showed augmented innate 
immune responses upon activation in vitro. 
 
4.1.6 PPARγ  controls astrocytic CCL2-production in myeloid cells  
 
A number of studies indicate that the CCL2 / CCR2-axis plays a crucial role for the 
pathogenesis of multiple sclerosis and EAE60,100. CCR2 and its ligand CCL2 are important 
for emigration of inflammatory monocytes, bearing CCR2 on their surface, from the bone 
marrow and immigration into the inflamed tissue among a CCL2-gradient. 
So far, data of this thesis reveal an involvement of PPARγ in myeloid cells in modulation 
of local CCL2-production within the CNS (Figure 2b) during the effector phase of EAE. 
As astrocytes are known to be the main producer of CCL2 within the CNS6,121, we 
hypothesized that activated myeloid cells might trigger astrocytic CCL2-release during 
EAE and that this interaction might be influenced by PPARγ in myeloid cells. 
To evaluate this assumption in vitro, wildtype astrocytes were activated with LPS and 
IFNγ or cocultured with preactivated PPARγKO or PPARγWT BM-Ms or pMg. CCL2-
release was examined by ELISA after 24h.  
Upon stimulation with LPS and IFNγ, CCL2 production in astrocytes was 7-fold higher. 
Furthermore, CCL2-release was significantly 2-fold higher in macrophages (Figure 8a) and 
microglia (Figure 8b). Interestingly, coculture of astrocytes with macrophages (Figure 8a) 
or microglia (Figure 8b), that were prestimulated for 1h, increased CCL2-production 
compared to unstimulated astrocytes. Importantly, this macrophage- or microglia-mediated 
activation was regulated by PPARγ, as PPARγ-deficiency in myeloid cells resulted in 
enhanced CCL2-release into the supernatant.  
In contrast, T cells, activated for 72h with or without TH17-inducing conditions did not 
produce relevant amounts of CCL2 (Figure 8c). 
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Figure 8 CCL2-release by astrocytes cocultured with PPARγKO or PPARγWT 
macrophages or microglia  
(a-b) CCL2-production of astrocytes, (a) BM-Ms or (b) pMg or coculture: wildtype astrocytes 
were cocultured with PPARγKO or PPARγWT (a) BM-Ms or (b) pMg at a ratio of 1:1. Cells were 
stimulated with 1µg/ml LPS and 10ng/ml IFNγ. Supernatants were collected after 48 h and CCL2-
production was determined by ELISA. (c) Splenic T cells were isolated from a C57BL/6 mouse by 
immunomagnetic cell separation using CD4-MACS beads, activated by plate-bound αCD3 and 
αCD28 antibody for 72 h, with or without TH17-inducing conditions. CCL2 release was 
determined in the supernatant by ELISA. 
Data are expressed as mean ± SEM (n=5). *** p<0.001 
 
In conclusion, these results showed that myeloid cells can activate astrocytes producing 
high levels of CCL2: the chemokine that attracts CCR2+ inflammatory monocytes. 
 
4.1.7 Inflammatory monocytes are the main myeloid cell population 
controlled by PPARγ  during EAE 
 
Several reports indicate a prominent role for a CCR2-bearing subpopulation of myeloid 
cells, the ‘inflammatory monocytes’97, for the progression of EAE98,100. This cell 
population can be discriminated from resident monocytes: inflammatory monocytes are         
CCR2+Ly-6ChiCD62L+CX3CR1lo, and the resident monocytes are                                  
CCR2–Ly-6CloCD62L–CX3CR1hi 97. 
As the preceding data show an important role of PPARγ in myeloid cells during the 
effector phase of EAE, the influence of PPARγ in inflammatory monocytes during EAE 
was further analyzed. 
To directly assess the role of PPARγ in inflammatory monocytes during the effector phase 
of EAE, CD115+ monocytes were isolated from healthy LysM-PPARγKO or LysM-
PPARγWT mice and injected into MOG-immunized C57BL/6 EAE mice during the effector 
phase of EAE. Disease score was monitored daily and, on day 10 after the first monocyte 
transfer, CD40-expression on the surface of macrophages and microglia was analyzed. 
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Although not significant due to small animal numbers, administration of 1 x 107 PPARγWT 
inflammatory monocytes per mouse resulted in a slightly augmented disease course during 
ongoing CNS-inflammation which was visible already from day one after transfer 
(Figure 9a). In mice that received PPARγKO inflammatory monocytes, the course of disease 
was even more aggravated in comparison to mice that received wildtype inflammatory 
monocytes.  
Moreover, analysis of the CD40-expression on CNS-derived macrophages and microglia 
on day ten after the first transfer revealed a slight increase in the percentage of CD40-
expressing cells in mice that received PPARγWT monocytes. This amount was even more 
increased in mice that received PPARγKO monocytes (Figure 9b). These findings indicate 
that CD40 is upregulated on microglial cells and macrophages during CNS-inflammation 
in a PPARγ-dependent way. 
 
 
 
Figure 9 PPARγ in moncytes limits monocyte-mediated severity of disease during EAE  
(a) Mean clinical score of EAE-diseased C57BL/6 mice. On days 12, 14, 16 and 19 after active 
EAE immunization, 1 x 107 CD115+ monocytes derived from bone-marrow of healthy LysM-
PPARγKO or LysM-PPARγWT mice were injected i. v. into EAE mice. Control mice did not receive 
monocytes. Graph depicts mean clinical score ± SEM, n=5 per group. (b) 10 days after the first 
monocyte transfer, CNS macrophages and microglia were isolated and analyzed for CD40 
expression. Graph depicts the mean percentage of CD40+ macrophages or microglia ± SEM (n=5 
per group). 
 
It is known that depletion of inflammatory monocytes results in an ameliorated course of 
disease98,100. As we observed that transfer of PPARγKO inflammatory monocytes 
aggravates EAE (Figure 9a), we hypothesized that PPARγ plays a crucial role for CNS-
inflammation during EAE especially in this myeloid cell population. Therefore, we 
performed depletion of this population to address the question, if diminution of 
inflammatory monocytes in LysM-PPARγKO and LysM-PPARγWT mice may abolish the 
observed differences during the effector phase of EAE. 
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To this end, we used an αCCR2 antibody (MC-21), which selectively depletes     
CCR2+Ly-6Chi, but not CCR2–Ly-6Clo monocytes in vivo122. (EAE-experiment and 
monocyte depletion was performed with Stephanie Hucke.) 
LysM-PPARγKO and LysM-PPARγWT mice were immunized with MOG35-55 in CFA and 
20µg MC-21 or the appropriate isotype control were injected daily on days 13 to 17 after 
MOG-immunization. 
Application of the MC-21 antibody resulted in approximately 85 % depletion of 
inflammatory monocyes in the periphery of LysM-PPARγKO and LysM-PPARγWT mice, 
compared to isotype controls (Figure 10a). 
As expected, depletion of inflammatory monocytes resulted in amelioration of the disease 
course from day one after the first MC-21 injection in both, LysM-PPARγKO and LysM-
PPARγWT mice (Figure 10b). Importantly, depletion of inflammatory monocytes 
completely abolished the differences that were observed between isotype treated LysM-
PPARγKO and LysM-PPARγWT mice (Figure 10b). This observation indicates 
inflammatory monocytes represent the most important population of myeloid cells 
regulated by PPARγ during EAE. 
To further investigate the extent of inflammation within the CNS of MC-21-treated EAE 
mice, mRNA-levels of inflammatory mediators were analyzed by quantitative real-time 
RT-PCR. As expected, within the isotype control group, mRNA levels of the inflammatory 
cytokines IL-1β, IL-12, and IFNγ as well as iNOS were increased in the brain tissue of 
LysM-PPARγKO EAE mice compared to wildtype littermates (Figure 10c), which is in line 
with previous results (Figure 2a+b). Importantly and in accordance to the literature, 
mRNA-levels of inflammatory cytokines were decreased in brains of mice treated with 
MC-21. Furthermore, differences in pro-inflammatory mediators between LysM-PPARγKO 
and wildtype EAE mice (Figure 2a) were completely abrogated upon treatment with      
MC-21. Similar results were found for mRNA levels of chemoattractant mediators like 
CCL2, CCL3, CCL5, and CXCL10 (Figure 10c). 
Furthermore, the activation status of macrophages and microglia within the CNS in         
MC-21-treated EAE mice was analyzed during the effector phase of EAE.  
As shown in Figure 10d, alterations in CD40 or MHC-II-expression were not observed 
between MC-21-treated and isotype control (histograms), indicating that MC-21-treatment 
does not affect myeloid cell activation status on a single cell level. However, the 
percentage of MHC-II- and CD40-expressing macrophages was reduced in the MC-21 
treated mice compared to the isotype control-treated mice. 
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Figure 10 Depletion of inflammatory monocytes ameliorated disease course during EAE 
and diminished differences between LysM-PPARγKO and LysM-PPARγWT 
mice (Experiments performed with Stephanie Hucke) 
(a-d) Depletion experiment of inflammatory monocytes in LysM-PPARγKO or LysM-PPARγWT 
mice by the αCCR2 antibody (MC-21) during EAE. (a) 8 h after first injection of MC-21 or 
isotype control, depletion was monitored in the blood. Living cells were gated on CD11b, numbers 
in dotplots indicate the percentage of Ly-6ChiLy-6G- cells ± SEM (population in upper gate) and 
Ly-6CloLy-6G- cells ± SEM (population in lower gate). (b) Mean clinical score ± SEM of LysM-
PPARγKO or LysM-PPARγWT EAE mice of two independent experiments is shown. EAE was 
induced by active immunization and inflammatory monocytes were depleted by repetitive injection 
of 20 µg MC-21 or isotype control at indicated timepoints (arrows). Graph depicts LysM-PPARγKO 
EAE mice administered MC-21 (red squares; n=20) or isotype control (black squares; n=15) and 
LysM-PPARγWT EAE mice that received MC-21 (blue triangles; n=20) or isotype control (grey 
triangles; n=12). (c) On day 21 after immunization, expression of inflammatory mediators and 
chemokines was determined by quantitative real-time RT-PCR (n=5, MC-21; n=10, isotype 
control). Data were normalized to endogenous GAPDH and are expressed as n-fold induction 
compared to healthy LysM-PPARγWT and LysM-PPARγKO mice, respectively. Data are displayed 
as mean ± SEM. (d) Expression of MHC-II and CD40 was analyzed in CNS-macrophages by flow 
cytometry on day 21 after immunization (n=3, isotype control; n=5 MC-21).  
Graphs show mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
 
These data clearly show that transfer of PPARγ-ablated inflammatory monocytes during 
the effector phase aggravates EAE (Figure 9a), whereas depletion of this cell population 
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results in an ameliorated course of disease, which is comparably in LysM-PPARγKO and 
wildtype mice (Figure 10b). 
Together, the observation that depletion of inflammatory monocytes completely abolished 
the differences in the course of disease observed between LysM-PPARγKO mice and their 
wildtype littermates identify inflammatory monocytes as the main target for PPARγ-
activation within the population of myeloid cells.  
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5 Discussion 
 
The importance of auto-reactive encephalitogenic T cells for disease initiation in MS and 
EAE has been analyzed extensively27,111,112. However, several publications recently 
focused on myeloid cells like peripheral macrophages and resident microglial cells 
involved in CNS inflammation during the development of EAE: For example, microglial 
cells are important for development and disease progression of EAE by activation of 
encephalitogenic T cells118,123 and secretion of neurotoxic mediators like NO, ROS, and 
TNFα, which directly contribute to tissue damage within the CNS64. More recently, 
peripheral inflammatory monocytes have been reported to contribute to disease progression 
during EAE98,100. 
Importantly, activation of PPARγ in monocytes and macrophages augmented release of 
pro-inflammatory and neurotoxic mediators like IL-1β, IL-6, TNFα, and iNOS75,72. 
Based on these findings, the major interest of this thesis was to analyze the role of PPARγ 
in myeloid cells on the inflammatory and neurotoxic immune responses and its effect on 
the development of EAE.  
 
Various inflammatory mediators produced by microglial cells and macrophages have been 
linked to activation and recruitment of disease-promoting cells during EAE and MS, 
respectively6,45,56,120. To address the role of PPARγ in myeloid cells during EAE, 
alterations of these different parameters due to PPARγ ablation were analyzed in this work. 
In vitro analysis demonstrated that PPARγ controls the production of TNFα, IL-6, NO, 
ROS, and IL-12 in bone-marrow-derived macrophages and primary microglial cells 
(Figure 7a+b). IL-12 and IL-6 are cytokines known to be involved in the polarization of 
TH1 cells and TH17 cells. These two important T cell subsets are involved in the onset and 
maintenance of EAE and MS16,41. Therefore, a suppression of IL-6 and IL-12 production in 
macrophages and microglial cells by PPARγ might control activation and differentiation of 
these T cell subsets during the development of EAE. This hypothesis is supported by the 
observation that LysM-PPARγKO mice showed a significant increase in the quantity of 
T cells within the CNS compared to LysM-PPARγWT mice (Figure 1d). Although the 
percentage of activated CD4+ T cells in the draining lymph nodes and the CNS did not 
show an increase of IFNγ- or IL-17A-producing T cells in the LysM-PPARγKO mice 
compared to wildtype littermates (Figure 5a+b), the absolute numbers of T cells within the 
CNS were increased in LysM-PPARγKO mice compared to wildtype controls (Figure 1d). 
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TNFα and IL-6 refer to activation of macrophages and microglial cells, and TNFα as well 
as NO have been implicated to directly contribute to MS pathology63: TNFα induces NO-
synthase124,125, which leads to cell death of oligodendrocytes126. As oligodendrocytes 
synthesize and maintain the myelin sheath, destruction of these cells results in enhanced 
demyelination and impaired remyelination during ongoing CNS autoimmunity62-64. As 
PPARγ controls release of these neurotoxic mediators in both, macrophages (Figure 7a) 
and microglia (Figure 7b) and mice lacking PPARγ in myeloid cells showed a significantly 
higher demyelination during EAE (Figure 1c), a prominent role of PPARγ in these cells 
can be assumed for the reduction of demyelination and neuronal damage.  
The surface molecules MHC-II and CD40 are both known to be important for the 
development and perpetuation of disease. Presentation of self-antigens presented by 
myeloid cells in the context of MHC-II to encephalitogenic, auto-reactive T cells, is a 
crucial step for T cell reactivation and initiation of disease as inhibition of                  
MHC-II-expression ameliorates the clinical course of EAE127. Furthermore, lack of     
CD40-expression within the CNS decreases the efficacy of T cell priming118. These data 
identify PPARγ in macrophages and microglia as a prominent regulator for the expression 
of these molecules, as CD40- as well as MHC-II-expression were increased in PPARγ-
ablated microglia and CNS-derived macrophages compared to myeloid cells derived from 
wildtype mice (Figure 4b-e).  
We therefore suggest that PPARγ in myeloid cells does not only control pro-inflammatory 
responses involved in innate immune activation and organ damage, but also controls the 
capacity of these cells to locally reactivate invading encephalitogenic T cells within the 
CNS.  
 
Taken together, PPARγ in myeloid cells is a potent regulator for innate and adaptive 
immune responses important for the development and perpetuation of EAE and MS: On 
the one hand, production of neurotoxic mediators like TNFα and ROS as well as iNOS is 
controlled by PPARγ, thus, leading to demyelination and neuronal damage (Figure 11a). 
On the other hand, PPARγ in myeloid cells regulates several components regarding signal 
1, 2, and 3 which are required for T cell priming and activation: MHC-II (signal 1), CD40 
(signal 2), and IL-6, IL-12 (signal 3) were all controlled by PPARγ in myeloid cells 
(Figure 11b). Therefore, PPARγ in macrophages and microglial cells is a promising target 
for innate and adaptive immune responses promoting the development and perpetuation of 
EAE. 
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Figure 11 PPARγ in macrophages and microglia is involved in the regulation of innate 
and adaptive immune responses promoting EAE-development and perpetuation 
of disease            
(a) Expression of neurotoxic mediators by myeloid cells is controlled by PPARγ. (b) Upregulation 
of signal 1 (MHC-II), signal 2 (CD40) and signal 3 (IL-6, IL-12) is regulated by PPARγ. 
 
Also in vivo we could demonstrate that PPARγ in myeloid cells controls the production of 
different pro-inflammatory cytokines, as well as neurotoxic mediators within the CNS 
(Figure 2a) affecting demyelination, neuronal damage (Figure 1 c) and the disruption of the 
BBB128, leading to an aggravated disease course in LysM-PPARγKO mice compared to 
wildtype littermates (Figure 1b). Together, these data hence provide evidence that 
regulation of these parameters by PPARγ in myeloid cells might influence the development 
and perpetuation of disease during EAE and MS. Beside cytokines and pro-inflammatory 
mediators implicated in disease progression and direct organ damage, also levels of several 
chemokines like CCL2, CCL3, and CXCL10 were controlled by PPARγ in myeloid cells 
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during the effector phase of EAE (Figure 2b). These chemokines specifically target cells of 
the immune system and recruit monocytes, macrophages, microglia, and T cells to the site 
of inflammation during EAE. In line with this, histological analysis of the spinal cord of 
EAE-diseased mice showed that PPARγ-ablation in myeloid cells resulted in an increased 
infiltration of T cells and macrophages during the effector phase of EAE (Figure 2b and 
Figure 1d), which in turn results in recruitment and infiltration of further immune cells 
reflected by increased numbers of T cells and macrophages. 
In conclusion, during EAE PPARγ in myeloid cells regulates the production of pro-
inflammatory mediators activating immune cells and neurotoxic mediators, leading to 
neuronal and axonal damage, and the release of chemokines resulting in further 
recruitment of immune cells thus perpetuating local inflammation. These observations 
underline the hypothesis that PPARγ in myeloid cells plays a prominent role for disease 
progression during the effector phase of EAE. 
 
Importantly, differences between LysM-PPARγKO mice and LysM-PPARγWT mice were 
observed exclusively during the effector phase of EAE, which suggests that PPARγ in 
myeloid cells is a dispensable factor during the initial T cell-dependent phase of disease 
(Figure 1b). Besides their already discussed inflammatory and neurotoxic effects, myeloid 
cells may also contribute to T cell priming. Therefore the question arose, whether the 
aggravated course of disease during the effector phase in LysM-PPARγKO mice compared 
to wildtype littermates is due to an increased T cell priming in the periphery during the 
initial priming phase. 
As differences in T cell priming were not observed in LysM-PPARγKO mice compared to 
wildtype littermates both in the periphery and within the CNS during EAE (Figure 5a-c), it 
can be concluded that initial T cell activation in the periphery by antigen-presenting cells 
was not modulated by PPARγ. Moreover, upon adoptive transfer of primed wildtype CD4+ 
T cells into LysM-PPARγKO mice still revealed a significant difference in disease severity, 
thus demonstrating that these observed differences are not due to T cell priming 
(Figure 5d). 
In conclusion, these data do not support a relevant involvement of PPARγ in macrophages 
for peripheral T cell priming during disease induction. Instead, it can be assumed that 
PPARγ in myeloid cells is involved in limiting recruitment of T cells to the inflamed CNS 
during the effector phase of EAE, as the number of T cells was increased in the CNS of 
LysM-PPARγKO mice compared to wildtype littermates at later timepoints (Figure 1d). 
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In EAE-experiments Natarajan et al. revealed that PPARγ-deficient heterozygous mice 
developed an exacerbated course of disease with prolonged clinical paralysis compared to 
their wildtype littermates129. Our group has previously demonstrated that a conditional 
knock-out of PPARγ in CD4+ T cells resulted in a selective increase of TH17 cells within 
the CNS55, which are pivotal for the development of EAE130. By augmenting TH17 
differentiation, the PPARγ-ablation in CD4+ T cells resulted in a disease aggravation 
during the initial priming phase but not the effetor phase during EAE 55. Interestingly, the 
data presented in this thesis reveal that PPARγ in myeloid cells regulates the effector phase 
of EAE only (Figure 1b), indicating that PPARγ exerts distinct immune-regulatory 
properties in different immune cell populations during different phases of CNS 
autoimmunity. 
Although the contribution of astrocytes to EAE or MS is widely discussed70,131,132, 
astrocytes are known to serve as APCs in vitro and contribute to release of pro-
inflammatory cytokines and chemokines in response to a variety of stimuli67,133 under the 
control of PPARγ in vitro134. However, disease pathology mediated by other CNS-resident 
cells like astrocytes and neuronal cells was not influenced by PPARγ as reflected by 
unaltered EAE disease course in Nestin-PPARγKO mice which lack PPARγ in astrocytes 
and neuronal cells (Figure 6b).  
In summary, these different effects of PPARγ in various cells demonstrate different 
functions of PPARγ in distinct cell populations during EAE: In CD4+ T cells PPARγ-
ablation augmented TH17 differentiation resulting in an aggravated initial priming phase, 
whereas PPARγ-ablation in myeloid cells caused a reinforcement of the inflammation and 
cell recruitment resulting in an aggravation during the effector phase, but PPARγ-ablation 
in other CNS-resident had cells no effect on the course of disease. 
 
Systemic activation of PPARγ by oral application of a pharmacological PPARγ agonist 
(e.g. Pio), has been shown to ameliorate the course of disease during EAE55,88. In ex vivo 
experiments, our group previously showed that systemic activation of PPARγ by Pio 
resulted in reduced numbers of TH17 cells during EAE within the CNS55. Moreover, 
systemic activation of PPARγ by i.p. administration of different PPARγ agonists decreased 
CNS inflammation and demyelination during the course of EAE135. Furthermore, 
activation of PPARγ by these agonists affected also macrophage activation in vitro135. 
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Based on these findings, it can be hypothesized that pharmacological activation of PPARγ 
not only affects T cell activation but might also regulate inflammatory responses in 
monocytes, macrophages, and microglial cells during EAE. Accordingly, in vitro 
activation of PPARγ in macrophages and microglia showed reduced production of pro-
inflammatory cytokines, neurotoxic mediators, chemokines, and surface markers, which 
are crucial for cell-cell-interaction during the development and perpetuation of EAE. 
In light of these promising results from animal studies, Klotz et al. demonstrated a 
beneficial role of PPARγ in human immune cells: activation of PPARγ ex vivo suppressed 
TH17 differentiation of CD4+ T cells derived both from healthy individuals and MS 
patients55. Furthermore, in vitro activation of PPARγ revealed an anti-inflammatory and 
anti-proliferative effect in peripheral blood mononuclear cells (PBMCs) from healthy 
controls but also from MS patients91 and in these patients a reduced expression of PPARγ 
was found. Interestingly, both PPARγ expression levels and PPARγ activity could be 
increased by activation with Pio when given before an acute inflammatory event91. 
Therefore, it can be hypothesized that continuous activation of PPARγ might control 
disease progression during MS if administration would start prior to an acute relapse.  
 
Based on the observations made in this study, an important question arose: which subgroup 
of myeloid cells is the main target for PPARγ-mediated regulation during EAE. Based on 
the literature, the subpopulation of inflammatory monocytes seemed to be the most 
promising target for PPARγ activation during EAE. 
Recruitment of these cells into the CNS has been shown to be a crucial step for the 
progression and perpetuation of CNS inflammation during EAE98,100. Various 
examinations showed that the chemokine CCL2 is essential for recruitment of 
inflammatory monocytes in this process60,98,100. Within the CNS, this chemokine is mainly 
produced by astrocytes, attracting inflammatory monocytes into the CNS6,121. 
In this work it was demonstrated that astrocytic CCL2-release is triggered by activated 
macrophages and microglial cells, and that the extent of astrocytic CCL2 production 
depends on PPARγ-activity in myeloid cells, as pre-activation of macrophages and 
microglia elicited CCL2-release in astrocytes, and this inflammation-dependent CCL2-
release of astrocytes was significantly higher upon co-culture with PPARγ-deficient 
macrophages or microglia compared to coculture with wildtype myeloid cells 
(Figure 8a+b).  
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Oh et al., showed that human astrocytes produced CCL2 in response to TNFα and           
IL-1β136. Since expression of these cytokines was increased in PPARγ-deficient 
macrophages and microglia (Figure 3, Figure 7a+b), we hypothesize that enhanced levels 
of IL-1β and TNFα in the CNS of EAE diseased LysM-PPARγKO mice might trigger high 
levels of astrocytic CCL2-release in vivo. Importantly, this increase of CCL2 was observed 
in the CNS in of LysM-PPARγKO mice compared to LysM-PPARγWT during the course of 
EAE (Figure 10c). 
Local production of CCL2 within the CNS results in recruitment of                       
CCR2+Ly-6ChiCX3CR1lo inflammatory monocytes, which have recently been shown to be 
crucial for disease progression during EAE98,100,118. By a combination of monocyte transfer 
experiments and selective antibody-mediated ablation of CCR2 expressing monocytes 
during EAE, we could provide evidence that these inflammatory monocytes are the main 
target population of PPARγ during the effector phase of EAE, as transfer of PPARγKO 
monocytes resulted in a more aggravated disease course than transfer of PPARγWT 
monocytes, whereas ablation of CCR2+ monocytes completely abrogated all differences 
observed during EAE of LysM-PPARγKO versus LysM-PPARγWT mice. 
 
Conclusion 
The role of PPARγ in regulating the release of neurotoxic and pro-inflammatory mediators 
by myeloid cells in vitro, which are important factors for development and perpetuation of 
EAE and MS, has been analyzed before75,72,115. However, in this thesis we could show for 
the first time that PPARγ in myeloid cells in vivo controls different factors promoting 
development as well as perpetuation of disease during the effector phase of EAE.  
In myeloid cells PPARγ controls the release of pro-inflammatory and neurotoxic mediators 
such as TNFα, NO, and ROS, causing an inflammatory milieu and neurotoxic damage 
(Figure 12d). Furthermore, we found that PPARγ in myeloid cells controls activation of 
macrophages and microglia reflected in the expression of surface molecules (CD40 and 
MHC-II) and cytokines (IL-6 and IL-12), promoting T cell-activation (Figure 12b). These 
signals promote development of TH1 and TH17 cells, which have been demonstrated to 
promote EAE and in turn activate myeloid cells118. Besides control of immune cell 
activation and reduction of neuronal damage within the CNS, PPARγ in myeloid cells 
controls release of IL-1β and TNFα by myeloid cells, and hence reduces astrocytic CCL2-
release known to be relevant for further macrophages and – importantly – CCR2+ 
inflammatory monocyte recruitment from the periphery to the site of inflammation 
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(Figure 12e). Moreover, PPARγ in myeloid cells controlled the release of T cell attracting 
chemokines during EAE (Figure 12f).  
 
 
Figure 12 PPARγ in myeloid cells controls different mechanisms during the development 
and perpetuation of EAE            
(a) Priming of auto-reactive cells in the periphery by APCs. (b) Upregulation of signal 1 (MHC-II), 
signal 2 (CD40) and signal 3 (IL-6, IL-12) in myeloid cells is regulated by PPARγ. (c) 
encephalitogenic T cells get reactivated by local APCs like microglia or CNS-invading 
macrophages. (d) Release of neurotoxic mediators resulting in demyelination is controlled by 
PPARγ in myeloid cells. (e) TNFα and IL-1β released by myeloid cells under the control of PPARγ 
trigger astrocytic CCL2-production, which attracts further CCL2+ inflammatory monocytes to the 
side of inflammation. (f) Release of further chemokines recruiting immune cells into the CNS is 
controlled by PPARγ in myeloid cells. Red arrows indicate parts regulated by PPARγ in myeloid 
cells during EAE. 
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Importantly, in this thesis we could show that depletion of inflammatory monocytes in the 
periphery diminished the differences found in the course of disease between LysM-
PPARγKO mice compared to LysM-PPARγWT mice, hence identifying this population as 
crucial target for PPARγ-mediated regulation of inflammation during the effector phase of 
EAE (Figure 13). 
 
 
Figure 13 Depletion of CCR2+ inflammatory monocytes abolishes differences observed 
between LysM-PPARγKO and LysM-PPARγWT mice  
Upon depletion of CCR2+Ly-6Chi inflammatory monocytes, differences in the severity of disease 
between LysM-PPARγKO and LysM-PPARγWT mice were abolished. Only activation of CNS-
macrophages and microglia on a single cell level were increased in LysM-PPARγKO mice 
compared to wildtype littermates. 
 
In conclusion, development of disease during EAE in LysM-PPARγKO mice in comparison 
to wildtype mice showed that PPARγ in myeloid cells controls disease during the effector 
phase of EAE in a complex way. We have shown that not only CNS-resident microglial 
cells, but also peripheral macrophages and especially inflammatory monocytes play an 
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important role during the development and perpetuation of disease. Therefore, myeloid 
cells represent a promising target for PPARγ-activation, which reduces inflammation, cell 
recruitment into the CNS, and neurotoxicity and thereby ameliorates severity of disease. 
Importantly, due to the fact that differences were only observed in the effector phase of 
disease, these data implicate that targeting myeloid cells for treatment of CNS-
inflammation, e.g. by pharmacological PPARγ-activation, might still be effective when 
started after disease manifestation, which more closely reflects the human situation. 
Therefore, myeloid cells, especially inflammatory monocytes, exhibit a promising target 
for future therapy of CNS autoimmunity. 
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